var title_f21_29_21968="Unstable lateral malleolar fracture";
var content_f21_29_21968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Unstable lateral malleolar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In addition to the displaced, oblique fracture of the lateral malleolus (black arrows), widening of the medial joint space (white arrow), indicating ligament disruption, is also evident on this x-ray. This unstable injury requires surgical fixation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21968=[""].join("\n");
var outline_f21_29_21968=null;
var title_f21_29_21969="Recurrent microcystic adnexal carcinoma";
var content_f21_29_21969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Recurrent microcystic adnexal carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recurrence of microcystic adnexal carcinoma in the site of previous excision. There are few clinical changes to suggest recurrence, except for extensive firmness to palpation around the skin graft (A). Tissue invasion by this recurrent microcystic adnexal carcinoma was more extensive than evident on clinical examination. Extensive surgical excision including resection of the underlying bone was required (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21969=[""].join("\n");
var outline_f21_29_21969=null;
var title_f21_29_21970="CNS tumor child histology";
var content_f21_29_21970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of childhood primary brain and CNS tumors by histology CBTRUS 2000-2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 652px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: CBTRUS (2008) Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Published by the Central Brain Tumor Registry of the United States.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21970=[""].join("\n");
var outline_f21_29_21970=null;
var title_f21_29_21971="Aortic regurgitation long axis echocardiogram";
var content_f21_29_21971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/57999/aorlngec_conv.mp4?title=Aortic+regurgitation+long+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-axis view of 2-D echocardiogram of bicuspid aortic valve showing dilated left ventricle and thickening of aortic valve leaflets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21971=[""].join("\n");
var outline_f21_29_21971=null;
var title_f21_29_21972="Onychomatricoma pincer nail";
var content_f21_29_21972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Pincer nail deformity secondary to onychomatricoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21972=[""].join("\n");
var outline_f21_29_21972=null;
var title_f21_29_21973="Endstage scleroderma lung PA";
var content_f21_29_21973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endstage scleroderma lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows small lung volumes, coarse asymmetric reticulation of the lungs with particular involvement of the right upper lobe. Note the markedly dilated transverse colon with fecal impaction due to lack of bowel motility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21973=[""].join("\n");
var outline_f21_29_21973=null;
var title_f21_29_21974="Color and pulsed Doppler sonogram of acardiac twin";
var content_f21_29_21974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Color and pulsed Doppler sonogram of acardiac twin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the arterial flow is going towards the fetal body, indicating perfusion from the normal co-twin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21974=[""].join("\n");
var outline_f21_29_21974=null;
var title_f21_29_21975="Osteoarthritis treatment";
var content_f21_29_21975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Osteoarthritis treatment (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21975/contributors\">",
"     Jerry M Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/29/21975/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ARTHRITIS INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA), also called arthritis, is a painful condition caused by a gradual loss of cartilage from the joints and, in some people, joint inflammation (",
"    <a class=\"graphic graphic_figure graphicRef73149 \" href=\"UTD.htm?28/20/28993\">",
"     figure 1",
"    </a>",
"    ). Arthritis can affect almost any joint, although it occurs most frequently in the hands, knees, hips, and spine. Common symptoms include pain, stiffness, and difficulty moving the joint easily.",
"   </p>",
"   <p>",
"    Arthritis is a chronic condition that gradually worsens over time. However, arthritis treatment can often reduce your symptoms, can allow you to stay active, and can possibly slow the progression of this condition. Treatment includes a combination of nonpharmacologic therapies (therapies other than drug therapy), drug therapy, and, in some cases, surgery.",
"   </p>",
"   <p>",
"    Arthritis treatment is tailored to you and is based upon how severe your pain and stiffness are, which joints are affected, and how well a particular treatment works. It is important to work with a healthcare provider to create an effective and acceptable long-term plan for living with arthritis.",
"   </p>",
"   <p>",
"    This topic review discusses arthritis treatments. A separate article discusses arthritis symptoms and diagnosis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"     \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS TREATMENT WITHOUT MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of treatments other than medications. These can substantially improve your arthritis symptoms, and they are usually the first treatments recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis symptoms are typically worsened by activity and are improved with rest. However, a complete lack of activity can lead to a loss of muscle and joint stiffness. If arthritis flares and causes significant pain and inflammation, your healthcare provider may recommend rest for 12 to 24 hours, followed by a return to usual activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is strongly linked to the development of arthritis of the knee. Weight loss, even modest weight loss, appears to lower this risk. It is not known if weight loss slows the worsening of arthritis in joints that are already affected. However, weight loss may reduce joint pain in weight-bearing joints, such as the hips and knees. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical therapy and exercise programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy and exercise improve flexibility and strengthen the muscles surrounding the joints. People who exercise regularly despite their arthritis will typically have less pain and better function than those who are inactive. A separate article discusses exercise and arthritis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"     \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Orthoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthoses are devices that help to keep the joints aligned and functioning correctly. There are many different types of orthoses that can reduce symptoms and that can help maintain function in people with osteoarthritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-cushioned shoes and orthotic shoe inserts may reduce stress on the joints of the spine and leg.",
"     </li>",
"     <li>",
"      Splints that immobilize the joints can reduce pain and inflammation, and many splints can be worn throughout the day and night. Braces can help stabilize unstable joints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assistive devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Canes, walkers, electric powered seat lifts, raised toilet seats, and tub and shower bars can reduce the stress on joints and can make it easier to perform daily tasks. A physical therapist may suggest these and other assistive devices, depending upon the severity and location of your arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have linked certain vitamins to joint health, but the role of vitamins in arthritis treatment is uncertain. Osteoarthritis is less likely to worsen in people who have a high dietary intake of vitamin C (ascorbic acid) and a high dietary intake and high blood levels of vitamin D. However, it is unknown if supplementation with these vitamins has the same effects or if high dietary intakes of vitamins can prevent the onset of osteoarthritis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"     \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Heat and cold therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applying heat and cold to arthritic joints can help to control arthritis symptoms such as pain and stiffness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heat therapy &mdash; Heat relieves pain and stiffness in arthritic joints. Heat can be applied to the joints with hot packs, hot water bottles, heating pads, or electrically heated mittens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to avoid burning the skin with heat therapy. To avoid burns, hot water bottles should be filled with warm, not boiling, water. Heating pads should be set on a timer and used for no more than 20 minutes at a time. The heating pad can be reapplied after 20 minutes of no use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold therapy &mdash; Cold relieves pain in arthritic joints and reduces muscle spasms. Cold can be applied for short periods using ice packs or coolant sprays. People with certain medical conditions, such as the Raynaud phenomenon, should not use cold therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transcutaneous electrical nerve stimulation (TENS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A TENS unit delivers a mild electrical current to the skin, stimulating nerve fibers in the skin that may interfere with the transmission of pain signals from the arthritic joint.",
"   </p>",
"   <p>",
"    The use of TENS as an arthritis treatment is controversial. Some studies have found that those who use TENS for arthritis of the knee have reduced knee pain, a greater ability to bend the knee, and a reduced duration of morning stiffness. However, another study found that TENS was no more effective for relieving pain than the drug",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"     naproxen",
"    </a>",
"    (Aleve&reg;, Anaprox&reg;) or a placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Arthritis education and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis symptoms may cause you to feel frustrated, dependent upon others for help, and even depressed. These factors may reduce your motivation to stick with arthritis treatment.",
"   </p>",
"   <p>",
"    By learning more about osteoarthritis, you can better participate in your own care. It is important to discuss the options for the treatment of arthritis, the effects of arthritis on daily activities, and the strategies for coping with the limitations imposed by arthritis with your healthcare provider.",
"   </p>",
"   <p>",
"    Some studies suggest that psychosocial support may be as effective as drug therapy for reducing the symptoms of arthritis. Support can be achieved by building an informal support network or by participating in formal arthritis support group. Information about these groups is available below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Where to get more information'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapies have been evaluated to determine if they have any effect on osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dietary supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucosamine and chondroitin are dietary supplements that have received a lot of attention for their potential benefit in reducing pain and in slowing the progression of arthritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucosamine &mdash; Glucosamine HCL was no more effective in relieving arthritis pain or in improving function than placebo in a well-designed, controlled trial; it is possible that other formulations may be effective. Glucosamine does not appear to slow the worsening of arthritis over the long term [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21975/abstract/1\">",
"       1",
"      </a>",
"      ]. There are few side effects of glucosamine; it should not be used by patients who are allergic to shellfish.",
"     </li>",
"     <li>",
"      Chondroitin &mdash; Chondroitin used alone appears to provide little benefit for people with osteoarthritis. There are no significant side effects of chondroitin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of glucosamine and chondroitin sulfate has not proven to be better than placebo for pain relief or for functional improvement in patients with OA of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21975/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Traditional Chinese medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several components of traditional Chinese medicine, including herbs and acupuncture, may help control the arthritis symptoms in some people, although the benefits of these therapies have not been confirmed in large, well-designed clinical studies.",
"   </p>",
"   <p>",
"    Reumalex, willow bark, stinging nettle, Articulin F, devils claw, extract of soybean and avocado unsaponifiables (ASU), and Phytodolor may improve arthritis pain, while other herbs and combinations, such as Eazmov, Gitadyl, or ginger extract, are probably ineffective. If you are considering using herbal medicines, talk to your healthcare provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Capsaicin cream",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some people experience relief of arthritis pain when they apply creams containing",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/41/36500?source=see_link\">",
"     capsaicin",
"    </a>",
"    , the active substance in hot chili peppers. Capsaicin depletes a pain-causing substance in nerve endings and lessens the arthritis pain by about 30 percent in some people. Forty percent of people experience side effects when using capsaicin cream, including burning, stinging, and redness of the skin and especially of the eye.",
"   </p>",
"   <p>",
"    Applying substances such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33827?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    (DMSO) or using low power laser light, copper bracelets, or magnets are of questionable benefit. Chiropractic manipulation, acupressure, biofeedback, and homeopathy are popular but also have unproven benefits for arthritis symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS TREATMENT WITH MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy is a key component of an arthritis treatment plan. Many types of drugs are available. More detailed information is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pain relief medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesics relieve pain but do not have any effect on inflammation. These drugs are often recommended when arthritis pain does not respond to nonpharmacologic measures. Drugs in this class include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and opioid (narcotic) analgesics.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    (Tylenol&reg; and others) can relieve mild to moderate arthritis pain. To avoid the serious but rare side effects of kidney",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver damage due to acetaminophen, it is important to follow dosing instructions and to avoid drinking excessive amounts of alcohol.",
"   </p>",
"   <p>",
"    The pain of sudden, severe arthritis exacerbations may require treatment with narcotic analgesics such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?13/44/14021?source=see_link\">",
"     codeine",
"    </a>",
"    . Narcotics should be taken for only short periods of time because they can be addictive. They are often most effective when taken together with nonsteroidal antiinflammatory drugs (NSAIDs). Narcotics can also be combined with",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (eg, Tylenol 3 contains",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=see_link\">",
"     acetaminophen-codeine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) relieve pain and reduce inflammation. Many of the nonprescription products that are available for treating arthritis pain are NSAIDs. These drugs are often recommended before analgesics for people who have osteoarthritis and evidence of inflammation. They are also recommended for some people with noninflammatory OA who do not get adequate pain relief with simple analgesics. NSAIDs are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"     \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Joint injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of injections are used for people with arthritis pain: glucocorticoid (steroid) injections and injections of a liquid known as hyaluronate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Glucocoticoid (steroid) injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids can suppress inflammation and can relieve arthritis symptoms when injected into arthritic joints.",
"   </p>",
"   <p>",
"    Glucocorticoid injections may be recommended for people who have osteoarthritis confined to a few joints and who still have pain despite the use of NSAIDs. Glucocorticoid injections may also be recommended for people with osteoarthritis who cannot take NSAIDs.",
"   </p>",
"   <p>",
"    Joint injections have few side effects, but some people experience a brief flare of arthritis symptoms after an injection. There is also a small risk of joint infection. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"     \"Patient information: Joint infection (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids may damage certain joints when injected frequently. Therefore, clinicians recommend no more than three to four injections per year for each particular weight-bearing joint such as a knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hyaluronate injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal joint fluid contains a large amount of hyaluronate, which allows the joint fluid to be slippery. Synthetic hyaluronates may be injected into the knee to treat arthritis. After the injection, pain relief may last for several months. Hyaluronan (Hyalgan&reg;) and hylan-GF-20 (Synvisc&reg;) are two products that can be used that have similar effects. These agents are generally injected in the knee, but their use in other joints is being studied.",
"   </p>",
"   <p>",
"    Joint inflammation has occasionally occurred after this type of injection. As with steroids, there is a small risk of infection. Thus, if you develop severe joint pain after an injection, call your healthcare provider immediately.",
"   </p>",
"   <p>",
"    Hyaluronate injections are generally reserved for people with osteoarthritis who cannot take NSAIDs or who do not achieve adequate pain relief with them. People awaiting joint surgery may benefit from these injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;This drug is often recommended for people with inflammatory osteoarthritis that does not improve with nonpharmacologic therapies and NSAIDs. A clinician may recommend",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"     colchicine",
"    </a>",
"    for people who have frequent flares of osteoarthritis that is resistant to other treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (Plaquenil&reg;) has immune-modulating effects that reduce the inflammation of arthritis in some people. This drug may be recommended for people with severe inflammatory OA and for those who have bone damage related to osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is usually reserved for severe arthritis that significantly limits your activities and that does not respond to other arthritis treatments. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, surgery is recommended before arthritis causes complications such as muscle loss and joint deformities. Furthermore, those who undergo surgery should be in the best possible physical condition and should be prepared for rehabilitation after surgery.",
"   </p>",
"   <p>",
"    More detailed information about surgery for arthritis is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Arthroscopy and joint irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of arthroscopic surgery in people with arthritis is controversial. In one study, patients who had &ldquo;real&rdquo; arthroscopic treatment and joint irrigation were compared with others who had a &ldquo;sham&rdquo; procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21975/abstract/3\">",
"     3",
"    </a>",
"    ]. Those who had the &ldquo;sham&rdquo; surgery were taken to the operating room where the doctor simulated arthroscopic surgery (but did not perform the actual procedure). Post-procedure improvement in symptoms was similar in both groups.",
"   </p>",
"   <p>",
"    A selected group of patients with arthritis may benefit from arthroscopy. However, people with significant arthritis are more likely to benefit from other types of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Realignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be used to realign bones and other joint structures that have become misaligned because of long-standing arthritis. For the knee, realignment may shift weight bearing to healthier cartilage to relieve arthritis pain. This type of alignment may be recommended for younger and more active patients instead of joint replacement surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be used to permanently fuse two or more bones together at a joint. This may be recommended for badly damaged joints for which joint replacement surgery is not appropriate. Fusion may be recommended for joints of the wrist and ankle and for the small joints of fingers and toes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Joint replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be used to replace a damaged joint with an artificial joint. The most common reason for having joint replacement surgery is pain that is not controlled by a combination of nonpharmacologic and drug treatments.",
"   </p>",
"   <p>",
"    Joint replacement surgery dramatically relieves pain in people with severe arthritis of the hip or knee, and this benefit appears to last for at least three years. However, it may take up to one year before the benefits of joint replacement surgery become fully apparent.",
"   </p>",
"   <p>",
"    For more information about joint replacement, see appropriate topic reviews. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"     \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cartilage grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be used to graft new cartilage cells into damaged regions of cartilage. The benefits of cartilage grafting in arthritic joints are being studied. Cartilage grafting is likely to be most practical when the cartilage damage is confined to a very small area that is surrounded by normal cartilage. Current techniques are not helpful for people with large areas of thin or absent cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11167873\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"     Patient information: Osteoarthritis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"     Patient information: Hip replacement (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"     Patient information: Arthritis and exercise (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"     Patient information: Pseudogout (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25490?source=see_link\">",
"     Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"     Patient information: Paget disease of bone (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11167889\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"     Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     Patient information: Weight loss treatments (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"     Patient information: Arthritis and exercise (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"     Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"     Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"     Patient information: Joint infection (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"     Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     Clinical manifestations of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     Diagnosis and classification of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     Evaluation of the active adult patient with knee pain",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     Evaluation of the adult with hip pain",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=see_link\">",
"     Evaluation of the patient with hand pain",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"     Evaluation of the patient with neck pain and cervical spine disorders",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"     Glenohumeral osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"     Investigational approaches to the pharmacologic therapy of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"     Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"     Musculoskeletal complications in diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     Nonpharmacologic therapy of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link\">",
"     Pathogenesis of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=see_link\">",
"     Patient guidelines for weight-resistance training in osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     Pharmacologic therapy of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     Risk factors for and possible causes of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     Surgical therapy of osteoarthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"     Weight-resistance training in patients with osteoarthritis",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/arthritis.html\">",
"       www.nlm.nih.gov/medlineplus/arthritis.html",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"      <br/>",
"      (301) 496-8188",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Arthritis/default.asp\">",
"       www.niams.nih.gov/Health_Info/Arthritis/default.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Institute on Aging",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nia.nih.gov/health/publication/arthritis-advice\">",
"       www.nia.nih.gov/health/publication/arthritis-advice",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      American College of Rheumatology",
"      <br/>",
"      (404) 633-3777",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"       www.rheumatology.org/practice/clinical/patients/index.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Arthritis Foundation",
"      <br/>",
"      (800) 283-7800",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.arthritis.org/\">",
"       www.arthritis.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Patient support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Arthritis Forum",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"       file://arthritis.about.com/forum",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21975/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21975/abstract/1\">",
"      Rozendaal RM, Uitterlinden EJ, van Osch GJ, et al. Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial. Osteoarthritis Cartilage 2009; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21975/abstract/2\">",
"      Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21975/abstract/3\">",
"      Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21975/abstract/4\">",
"      Katz JN, Mahomed NN, Baron JA, et al. Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum 2007; 56:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21975/abstract/5\">",
"      Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 516 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21975=[""].join("\n");
var outline_f21_29_21975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ARTHRITIS INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OSTEOARTHRITIS TREATMENT WITHOUT MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical therapy and exercise programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Orthoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assistive devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Heat and cold therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transcutaneous electrical nerve stimulation (TENS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Arthritis education and support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Traditional Chinese medicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Capsaicin cream",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OSTEOARTHRITIS TREATMENT WITH MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pain relief medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Joint injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Glucocoticoid (steroid) injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hyaluronate injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OSTEOARTHRITIS SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Arthroscopy and joint irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Realignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Joint replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cartilage grafting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H331\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11167873\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11167889\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Patient support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/516|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/20/28993\" title=\"figure 1\">",
"      Osteoarthritis PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=related_link\">",
"      Evaluation of the patient with hand pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=related_link\">",
"      Pathogenesis of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=related_link\">",
"      Patient guidelines for weight-resistance training in osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25490?source=related_link\">",
"      Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=related_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=related_link\">",
"      Weight-resistance training in patients with osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_29_21976="Moxifloxacin (systemic): Drug information";
var content_f21_29_21976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moxifloxacin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/51/2870?source=see_link\">",
"    see \"Moxifloxacin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9347830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9347899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avelox&reg;;",
"     </li>",
"     <li>",
"      Avelox&reg; ABC Pack;",
"     </li>",
"     <li>",
"      Avelox&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9347900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avelox&reg;;",
"     </li>",
"     <li>",
"      Avelox&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9347931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone;",
"     </li>",
"     <li>",
"      Respiratory Fluoroquinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9348067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute bacterial rhinosinusitis:",
"     </b>",
"     Oral, I.V.: 400 mg every 24 hours for 10 days or 5-7 days (Chow, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended in patients with beta-lactam allergy; may also be used if initial therapy fails, in areas with high endemic rates of penicillin nonsusceptible",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , those with severe infections, age &gt;65 years, recent hospitalization, antibiotic use within the past month, or who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic bronchitis, acute bacterial exacerbation:",
"     </b>",
"     Oral, I.V.: 400 mg every 24 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (including MDRSP):",
"     </b>",
"     Oral, I.V.: 400 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infections, complicated:",
"     </b>",
"     400 mg every 24 hours for 5-14 days (initiate with I.V.);",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend a treatment duration of 4-7 days (provided source controlled) for community-acquired, mild-to-moderate IAI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       M. genitalium",
"      </i>",
"     </b>",
"     <b>",
"      infections",
"     </b>",
"     (including confirmed cases or clinically significant persistent cervicitis, pelvic inflammatory disease or urethritis in patients who previously received azithromycin or doxycycline; unlabeled use): Oral, I.V.: 400 mg every 24 hours for 7-10 days (Manhart, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Complicated:",
"     </i>",
"     400 mg every 24 hours for 7-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     400 mg every 24 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tuberculosis, drug-resistant tuberculosis, or intolerance to first-line agents (unlabeled use):",
"     </b>",
"     Oral: 400 mg every 24 hours (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13658491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Community-acquired pneumonia (CAP) due to atypical pathogens (",
"      <i>",
"       M. pneumoniae, C. trachomatis, or C. pneumoniae",
"      </i>",
"      ), mild infection or step-down therapy in adolescents with skeletal maturity, (alternative to azithromycin) (IDSA/PIDS, 2011):",
"     </b>",
"     Adolescents (unlabeled): Oral: 400 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9348068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9348069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9348070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is required in mild, moderate, or severe  hepatic insufficiency (Child-Pugh class A, B, or C); however, use with caution in this patient population secondary to the risk of QT prolongation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9348115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in sodium chloride 0.8% [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avelox&reg; I.V.: 400 mg (250 mL) [contains sodium ~787 mg (34.2 mEq)/250 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avelox&reg;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avelox&reg; ABC Pack: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9347902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9347836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231731.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231731.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9348080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over 60 minutes; do not infuse by rapid or bolus intravenous infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9348033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, SWFI, LR;  do not add other medications to intravenous solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Doripenem, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9347942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate community-acquired pneumonia, including multidrug-resistant",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     (MDRSP); acute bacterial exacerbation of chronic bronchitis; acute bacterial rhinosinusitis (ABRS); complicated and uncomplicated skin and skin structure infections; complicated intra-abdominal infections",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9347943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of",
"     <i>",
"      Legionella",
"     </i>",
"     pneumonia; treatment of mild-to-moderate community-acquired pneumonia (CAP), including multidrug-resistant",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     (MDRSP) in adolescents with skeletal maturity; tuberculosis (second-line therapy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9347835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avelox&reg; may be confused with Avonex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9347995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&le;4%), dizziness (3%), insomnia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Chloride increased (&ge;2%), glucose decreased (&ge;2%), ionized calcium increased (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7%), diarrhea (6%), amylase decreased (&ge;2%), constipation (2%), vomiting (2%), abdominal pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Decreased serum levels of the following (&ge;2%): Basophils, eosinophils, hemoglobin, PT, RBC, neutrophils; increased serum levels of the following (&ge;2%): MCH, neutrophils, PT, WBC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin decreased/increased (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albumin increased (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: PO",
"     <sub>",
"      2",
"     </sub>",
"     decreased (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     0.1% to &lt;2%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, atrial fibrillation, bradycardia, cardiac arrest, edema, heart failure, hypertension, hypotension, palpitation, peripheral edema, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1%), agitation, anxiety, chills, confusion, depression, disorientation, fatigue, hallucinations, hypoesthesia, lethargy, malaise, nervousness, pain, restlessness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Allergic dermatitis, erythema, hyperhidrosis, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (1%), dehydration, hyperglycemia, hyperlipidemia, triglycerides increased, uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (1%), abdominal discomfort, abdominal distension, amylase increased, anorexia, appetite decreased, flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, lactic dehydrogenase increased, lipase increased, taste perversion, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria, vaginitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginal pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (1%), eosinophilia, hematocrit decreased, leukocytosis, leukopenia, aPTT increased, thrombocythemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (1%), AST increased, alkaline phosphatase increased, GGTP increased, liver function test abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site extravasation, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, chest pain (noncardiac), facial pain, limb pain, muscle spasms, musculoskeletal pain, myalgia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, candidiasis, fungal infection, night sweats, oral candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;0.1% (Limited to important or life-threatening): Agranulocytosis, anaphylactic reaction, anaphylactic shock, angioedema, aplastic anemia,",
"     <i>",
"      C. difficile",
"     </i>",
"     -positive diarrhea, cholestasis, deafness (reversible), ECG abnormalities, hearing impairment, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hypersensitivity reactions, INR decreased, interstitial nephritis, intracranial pressure increased, jaundice (cholestatic), myasthenia gravis exacerbation, nightmares, pancytopenia, peripheral neuropathy, photosensitivity/toxicity, pneumonitis (allergic), polyneuropathy, pseudomembranous colitis, pseudotumor cerebri, psychotic reaction, renal dysfunction, seizure, Stevens-Johnson syndrome, suicidal behavior/ideation, tendonitis, tendon rupture, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, ventricular tachyarrhythmias (including torsade de pointes and cardiac arrest [usually in patients with concurrent, severe proarrhythmic conditions]), vasculitis, vision loss (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9347991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to moxifloxacin, other quinolone antibiotics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9347992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Fulminant hepatitis potentially leading to liver failure (including fatalities) has been reported with use; patients should be advised to discontinue treatment and promptly report signs/ symptoms of hepatitis (eg, abdominal pain, jaundice, dark urine, pale stools).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may rarely cause moderate-to-severe phototoxicity reactions. Discontinue use if phototoxicity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. Tendon rupture may occur even after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with significant bradycardia or acute myocardial ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; glucose regulation may be altered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild, moderate, or severe hepatic impairment or liver cirrhosis; may increase the risk of QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of systemically-administered moxifloxacin (oral, intravenous) have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9347999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9348003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Absorption is not affected by administration with a high-fat meal or yogurt.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9347984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9347985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies moxifloxacin as pregnancy category C. Quinolone exposure during human pregnancy has been reported with other agents (see  Ciprofloxacin [Systemic], Ofloxacin [Systemic], and Norfloxacin [Systemic] monographs). To date, no specific teratogenic effect or increased pregnancy risk has been identified; however, because of concerns of cartilage damage in immature animals exposed to quinolones and the limited moxifloxacin specific data, moxifloxacin should only be used during pregnancy if a safer option is not available.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9347988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9347990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if moxifloxacin is excreted into breast milk. Breast-feeding is not recommended by the manufacturer. Although there is no information on the use of moxifloxacin during breast-feeding, other quinolones are considered compatible. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9348079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Take 4 hours before or 8 hours after multiple vitamins, antacids, or other products containing magnesium, aluminum, iron, or zinc.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avelox&reg; I.V. infusion (premixed in sodium chloride 0.8%) contains sodium 34.2 mEq (~787 mg)/250 mL.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9348117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Avelox Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/250 mL (250 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avelox ABC Pack Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (5): $125.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avelox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $751.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9348082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     WBC, signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avalox (AE, BH, BR, CH, CY, DE, EG, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Avelon (ZA);",
"     </li>",
"     <li>",
"      Avelox (AR, AU, BE, BF, BG, BJ, CI, CL, CN, CO, CR, CZ, DK, DO, EC, EE, ET, FI, GB, GH, GM, GN, GT, HK, HN, ID, IE, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, PA, PE, PH, PK, PL, PY, RU, SC, SD, SE, SG, SL, SN, SV, TH, TN, TR, TZ, UG, UY, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Bacterol (CO);",
"     </li>",
"     <li>",
"      Izilox (FR);",
"     </li>",
"     <li>",
"      Megaxin (IL);",
"     </li>",
"     <li>",
"      Moflodal (TW);",
"     </li>",
"     <li>",
"      Moxif (IN);",
"     </li>",
"     <li>",
"      Proflox (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9348034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moxifloxacin is a DNA gyrase inhibitor, and also inhibits topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9348036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; not affected by high-fat meal or yogurt",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.7 to 2.7 L/kg; tissue concentrations often exceed plasma concentrations in respiratory tissues, alveolar macrophages, abdominal tissues/fluids, uterine tissue (endometrium, myometrium), and sinus tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (~52% of dose) via glucuronide (~14%) and sulfate (~38%) conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Single dose: Oral: 12-16 hours; I.V.: 8-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug [20%] and glucuronide conjugates); feces (as unchanged drug [25%] and sulfate conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 52(RR-11):3-5. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16206101/pubmed\" id=\"16206101\" target=\"_blank\">",
"        16206101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2004, 27(9):671-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/15230648/pubmed\" id=\"15230648\" target=\"_blank\">",
"        15230648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16185172/pubmed\" id=\"16185172\" target=\"_blank\">",
"        16185172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 52(6):e177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16269178/pubmed\" id=\"16269178\" target=\"_blank\">",
"        16269178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manhart LE, Broad JM, and Golden MR, &ldquo;",
"      <i>",
"       Mycoplasma genitalium:",
"      </i>",
"      Should We Treat and How?&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(Suppl 3):129-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/22080266/pubmed\" id=\"22080266\" target=\"_blank\">",
"        22080266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(13):1352-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16510739/pubmed\" id=\"16510739\" target=\"_blank\">",
"        16510739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stass H, Kubitza D, Aydeniz B, et al, &ldquo;Penetration and Accumulation of Moxifloxacin in Uterine Tissue,&rdquo;",
"      <i>",
"       Int J Gynaecol Obstet",
"      </i>",
"      , 2008, 102(2):132-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/18501909/pubmed\" id=\"18501909\" target=\"_blank\">",
"        18501909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 2006, 331(6):334-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/16775443/pubmed\" id=\"16775443\" target=\"_blank\">",
"        16775443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated with Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/29/21976/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9845 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21976=[""].join("\n");
var outline_f21_29_21976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347830\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347899\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347931\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348067\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13658491\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348068\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348069\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348070\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348115\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347902\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347836\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348080\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348033\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347942\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347943\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347835\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347995\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347991\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347992\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299729\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347999\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348003\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347984\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347985\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347988\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347990\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348079\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348117\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348082\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961992\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348034\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348036\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9845|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=related_link\">",
"      Moxifloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/45/9940?source=related_link\">",
"      Moxifloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5924?source=related_link\">",
"      Moxifloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/51/2870?source=related_link\">",
"      Moxifloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_29_21977="Open surgical techniques for lower extremity vein ablation";
var content_f21_29_21977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Open surgical techniques for lower extremity vein ablation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21977/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21977/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21977/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/29/21977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical methods of vein ablation have largely been supplanted by less invasive methods, but remain the standard to which the minimally invasive techniques are compared. Patients with large varicose veins or complications of varicose veins are often best managed with open surgical techniques. Available techniques are chosen based upon the location, size, and extent of the patient's varicosities, and presence or absence of venous reflux.",
"   </p>",
"   <p>",
"    Open surgical techniques for lower extremity vein ablation will be reviewed here. Alternative treatment approaches to the treatment of chronic venous disease using cutaneous laser, sclerotherapy, radiofrequency ablation, and endovenous laser ablation are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"       \"Overview and management of lower extremity chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"       \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"       \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"       \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for surgical ablation are patients with persistent",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of venous disease after a minimum of three months of medical therapy and documented reflux (ie, retrograde flow &gt;0.5 second duration) as a source of their symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the introduction of minimally invasive methods of vein ablation, surgical therapy is reserved for the management of visible veins not amenable to treatment by lesser invasive means (ie, endovenous ablation), complications of varicose veins (ie, varicose vein hemorrhage, recurrent phlebitis), and refractory or recurrent venous ulceration. Surgical treatment may also be combined with less invasive treatment options in selected patients to reduce the number of treatments needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30250?source=see_link\">",
"     \"Endovenous laser ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of the surgical treatment of varicose veins is related primarily to the risk of anesthesia. For patients with significant cardiopulmonary comorbidities, techniques that use local or regional anesthetic are preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ablation of superficial varicosities is contraindicated if the superficial system represents the dominant venous outflow as in cases of deep vein obstruction or congenital absence of the deep venous system.",
"   </p>",
"   <p>",
"    Diabetes and moderate to severe peripheral artery disease are relative contraindications because these conditions are associated with an increased risk of non-healing wounds. When arterial and venous diseases are both identified, the arterial disease should be addressed first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Venous anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major superficial veins of the lower extremity include the great and small saphenous veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ). These and the saphenous accessory veins are collectively referred to as axial veins. The great saphenous vein joins the common femoral vein at the confluence of the superficial inguinal veins via the saphenofemoral junction. The small saphenous vein has more variable anatomy, especially with respect to the location of the saphenopopliteal junction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H22#H22\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Superficial venous system (As)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The deep veins of the lower extremity are contained within the deep muscle compartments bounded by the muscle fascia (",
"    <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H24#H24\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Deep venous system (Ad)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perforating veins are those that traverse the muscular fascia to connect the superficial veins with the deep veins. They are located anteriorly, posteriorly, laterally and medially in the thigh and calf.",
"   </p>",
"   <p>",
"    Bicuspid valves in the venous system direct flow in the superficial and deep veins from distal to proximal. With the exception of the foot, flow in the perforating veins is directed from superficial to deep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of chronic venous disease\", section on 'Normal venous anatomy and physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Saphenous nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The saphenous nerve is the terminal branch of the femoral nerve and provides sensory innervation to the medial aspect of the lower leg. It passes through the adductor canal, after which it becomes superficial and closely related to the saphenous vein. The saphenous nerve is most vulnerable to injury in the distal calf, where it actually adheres to the saphenous vein [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sural nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sural nerve is a sensory nerve supplying the lateral leg and foot, It courses with the small saphenous vein traveling posterior to the lateral malleolus toward the fifth toe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , antiplatelet agents, and nonsteroidal anti-inflammatory medications may be discontinued one week prior to surgery to reduce bleeding and subsequent hematoma formation, if the risk of doing so is not excessive.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    may be temporarily discontinued or bridging anticoagulation initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics are typically given even though most vein excision procedures are clean cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/2\">",
"     2",
"    </a>",
"    ]. Vein excision may have a higher risk for surgical site infection due to the need for groin dissection and a propensity for hematoma formation along the course of excised veins. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one randomized trial, antibiotic prophylaxis prior to great saphenous vein excision significantly improved postoperative ASEPSIS scores compared with controls (3 versus 6), and reduced other wound-related problems [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In this trial, specific patient factors, including obesity and current cigarette smoking, were associated with higher ASEPSIS scores. Factors such as diabetes and corticosteroid use were not able to be evaluated (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with venous ulceration, the choice of antibiotic is based upon the results of wound cultures, if available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacological thromboprophylaxis is generally not administered prior to surgical vein excision. Minimizing the duration of the surgical procedure (eg, less than 45 minutes), use of local anesthetic that allows muscular contractions during the operation, and early postoperative ambulation reduce the risk of deep vein thrombosis.",
"   </p>",
"   <p>",
"    Patients with a known thrombophilia, or those at high risk for venous thromboembolism should receive pharmacological thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of inherited thrombophilia\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to offer surgical vein",
"    <span class=\"nowrap\">",
"     excision/ligation",
"    </span>",
"    depends upon symptoms, response to medical therapy or prior intervention (eg, sclerotherapy, endovenous ablation), extent of lower extremity venous disease, and patient expectations.",
"   </p>",
"   <p>",
"    The risks of the procedure include bleeding, infection, vein recurrence, possible need for transfusion, phlebitis, deep venous thrombosis, and cutaneous nerve injury leading to numbness or paresthesias. A less than optimal cosmetic result may also occur due to hyperpigmentation and telangiectatic matting. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Complications of surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternatives to surgical ablation include compression therapy, endovenous ablation, or sclerotherapy. In the United States, there are no effective medications available for the treatment of superficial venous insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Systemic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent varicosities that do occur are usually smaller in caliber. Supplemental vein excision or sclerotherapy may be required to achieve the desired result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Compression stockings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the surgical method employed in vein ablation, compression in the form of elastic wraps (eg, ACE) or graduated compression stockings are useful to limit bruising and swelling in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/5\">",
"     5",
"    </a>",
"    ]. However, randomized trials have not found a benefit to wearing compression stockings with respect to postoperative pain, complications, return to work, or patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When elected, patients are prescribed Class II or higher compression stockings (eg, thigh-high or pantyhose), which they should obtain prior to the day of the scheduled procedure (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"UTD.htm?36/42/37547\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H7#H7\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Graduated compression stockings'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'Postoperative instructions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vein mapping/marking",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the patient standing, the veins that are to be removed are mapped (ie, marked with indelible ink) prior to the procedure. Patients should actively participate in this process to ensure that all the veins that concern them have been addressed. Near-infrared (IR) imaging using a wavelength of 880 nm to 930 nm may improve the accuracy of vein identification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57470073\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical vein removal is typically performed in the outpatient setting using local, regional, or general anesthesia, depending upon surgeon and patient preference. Light sedation can be achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , and for some procedures (eg, saphenous vein removal), a dilute anesthetic mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , bicarbonate, and epinephrine can be injected subcutaneously along the course of the marked veins to achieve a peau d&rsquo;orange appearance to reduce perioperative pain and improve hemostasis; this is referred to as tumescent anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57470085\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical techniques involve ligation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    removal of veins; the specific method chosen is based upon the location, size, and extent of the patient's varicosities, and presence or absence of venous reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57470044\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer to perform surgical vein removal on one leg at a time because the bilateral surgery is often not well tolerated. &nbsp;",
"   </p>",
"   <p>",
"    As an alternative to moving the patient to and from an operating room table, the author performs the procedure on a standard hospital gurney with the foot of the bed elevated. In doing so, the leg can remain elevated throughout the procedure and recovery period, which reduces bleeding.",
"   </p>",
"   <p>",
"    For saphenous vein stripping, the groin hair is trimmed to facilitate exposure of the saphenofemoral junction, and placement and adhesion of the postoperative dressing. The lower extremity is prepared circumferentially from the anterior superior iliac spine to the level of the ankle. Alcohol-containing skin preparation should be avoided because it can remove skin markings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous ulcerations, if present, are prepared last with a separate prep kit. The wounds are cleansed, dried, and covered with an occlusive dressing to limit transmission of microbes to the remainder of the operative field. Portions of the extremity that are affected with ulceration should be draped out of the sterile field.",
"   </p>",
"   <p>",
"    Blood loss during surgical removal of large varicosities can be significant, and the need for transfusion has been reported. Bleeding can be significantly reduced by elevation of the lower extremity during the procedure.",
"   </p>",
"   <p>",
"    Alternatively, tourniquets (eg, Esmarch, Lofquist cuff, Rhys-Davis Cuff) can be used during varicose vein surgery to reduce blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. A systematic review identified three randomized trials each supporting significantly decreased blood loss with the use of a tourniquet [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/13\">",
"     13",
"    </a>",
"    ]. Because of the small number of patients in each trial, and expected rarity of complications, no conclusions were drawn with respect to any potential complications (eg, nerve injury) from the use of the tourniquet.",
"   </p>",
"   <p>",
"    Once the procedure is completed, the extremity gauze dressings are placed on the wounds and compression in the form of elastic wraps (eg, ACE) or compression stockings is provided to help limit bruising. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Compression stockings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Saphenous vein inversion and removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient is sedated and anesthetized, a small incision is made 2 to 3 cm distal and lateral to the pubic tubercle. The junction of the great saphenous vein with the common femoral vein (ie, saphenofemoral junction) is identified and isolated. Anteromedial and posterolateral tributaries are ligated and divided; however, tributaries draining the abdominal wall are preserved by some surgeons.",
"   </p>",
"   <p>",
"    The great saphenous vein is divided, and the proximal end ligated near its junction with the common femoral vein. The vein stripper is passed retrograde through the open end of the divided vein distally. Due to the incompetence of the vein valves, the stripper should pass easily. A small skin incision is made over the tip of the stripper, which is palpated through the skin, usually near the knee. After incising the vein, a forceps is used to grasp the stripper and pull it through the incision.",
"   </p>",
"   <p>",
"    In the groin, the stripper is securely tied to the vein. The authors prefer not to use the mushroom tips supplied with the stripper because excessive tissue trauma and bleeding can result. The vein inverts on itself and the vein is removed by pulling the stripper distally. Tributary veins that are tethering the vein can be disrupted using a percussion strike on the skin with four fingers as the stripper advances. Once hemostasis is achieved by direct pressure along the vein bed, the groin incision is closed with interrupted, absorbable suture.",
"   </p>",
"   <p>",
"    A similar procedure can be used to strip the small saphenous vein. Care must be taken to avoid injury to the adjacent sural nerve.",
"   </p>",
"   <p>",
"    Cryostripping is a variation of traditional saphenous stripping and is limited to the treatment of the great saphenous vein. A specialized instrument is placed at the level of the previously ligated and divided saphenous vein, and supercooled. The vein freezes adhering to the device and is removed as the device is pulled out. The reported advantage of this method is potentially reduced postoperative bruising compared with conventional techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     High saphenous ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligation of the saphenous vein at the saphenofemoral junction alone, without vein removal, is not usually performed due to the high rate of recurrent varicose veins and persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    High ligation of the saphenous vein, however, is occasionally appropriate for selected patients with proximal superficial phlebitis that encroaches on the saphenofemoral junction, and who have a contraindication to anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ambulatory phlebectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excision and avulsion of superficial varicosities (ie, phlebectomy) through multiple tiny incisions is referred to as &ldquo;ambulatory phlebectomy&rdquo; or &ldquo;micro-stab avulsion phlebectomy.&rdquo;",
"   </p>",
"   <p>",
"    Ambulatory phlebectomy is useful for removing a wide range of non-saphenous and reticular veins that are unsuitable for treatment with sclerotherapy, or catheter ablation due to tortuosity. Ambulatory phlebectomy can be combined with saphenous inversion for complete treatment at a single session.",
"   </p>",
"   <p>",
"    We use an 18 gauge needle to make a series of punctures at intervals of 2 to 3 cm adjacent the course of the marked veins. Sequential venous segments are engaged with a variety of small, specially-designed crochet-like hooks, and are grasped and ligated or avulsed. Bleeding is controlled with direct pressure and limb elevation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450925705\">",
"    <span class=\"h2\">",
"     Transilluminated powered phlebectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another technique for vein removal relies on the use of a powered, mechanical aspirator called transilluminated powered phlebectomy (TIPP). The device is similar to devices used by orthopedic surgeons to shave off cartilage. The device consists of a long, narrow tube that has a rotating blade at its tip to macerate and aspirate the target vein. An illuminator (light source) is placed into the subcutaneous tissue through a counterincision to improve visualization of the target veins through the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following the administration of tumescent anesthesia, which is a mixture of saline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and epinephrine, the device is inserted adjacent the path of the target vein. The blade is activated and the vein is aspirated into the device and destroyed.",
"   </p>",
"   <p>",
"    The advantage of powered phlebectomy is the need for fewer incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/1\">",
"     1",
"    </a>",
"    ]; however, systematic reviews have found that TIPP is associated with more postoperative pain and hematoma formation compared with ambulatory phlebectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Another disadvantage of TIPP is the additional cost of the specialized equipment and supplies. Many patients with varicose veins also require management of saphenous reflux, which is often performed with an endovenous procedure. The combined equipment cost (ie, endovenous plus TIPP) may be prohibitive, especially since cosmetic outcomes with TIPP do not appear superior to the conventional",
"    <span class=\"nowrap\">",
"     ligation/excision",
"    </span>",
"    techniques described above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57470051\">",
"    <span class=\"h2\">",
"     Conservative venous ligation (CHIVA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative venous ligation (CHIVA; Conservatrice et H&eacute;modynamique de l'Insuffisance Veineuse en Ambulatoire) is an alternative method that aims to disrupt the column of hydrostatic pressure by disconnecting points of venous reflux while preserving venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The saphenofemoral or saphenopopliteal junction is ligated and divided but not excised (ie, stripped). Additional sites for ligation are identified with duplex ultrasound and clinical examination. A randomized trial of 501 patients found significantly lower visible vein recurrence rates at five years follow-up (intention-to-treat analysis) for patients managed with CHIVA compared with vein",
"    <span class=\"nowrap\">",
"     ligation/excision",
"    </span>",
"    with exam-guided vein marking or vein",
"    <span class=\"nowrap\">",
"     ligation/excision",
"    </span>",
"    with duplex-guided vein marking (40.1 versus 68.3 and 61.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Perforator ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refluxing perforator veins may be identified as a source for varicose vein clusters, and are typically ligated during the course of phlebectomy. For the treatment of severe chronic venous insufficiency and ulceration, it may also be appropriate to disrupt perforating veins contributing to ulcer formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Surgical perforator ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical perforator vein ligation is rarely performed given the availability of minimally invasive options. Minimally invasive techniques are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link&amp;anchor=H17#H17\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\", section on 'Perforator ablation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link&amp;anchor=H20#H20\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\", section on 'Specific anatomic considerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30250?source=see_link&amp;anchor=H715136892#H715136892\">",
"     \"Endovenous laser ablation for the treatment of lower extremity chronic venous disease\", section on 'Perforator ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open surgical perforator ligation (Linton procedure) was abandoned due to the magnitude of the operation and location of incisions in vulnerable areas of skin. The surgical site was prone to secondary ulceration when perforator ligation was not successful at reducing pressures within the skin.",
"   </p>",
"   <p>",
"    A less invasive surgical technique popularized in the 1980s used a videoscope placed through a small incision remote from the area of skin ulceration to identify and ligate perforating veins under direct vision. This technique, subfascial endoscopic perforator surgery (SEPS), was used to treat patients with refractory symptoms or ulceration, or recurrent ulceration associated with perforator reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/23\">",
"     23",
"    </a>",
"    ]. However, this technique has also been largely abandoned in favor of minimally invasive techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE INSTRUCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate postoperative pain is common. Depending upon the extent of the vein excision, patients can be managed with extra strength",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or acetaminophen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    . Nonsteroidal anti-inflammatory agents may be added in patients who develop a significant phlebitic reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H31\">",
"     'Superficial thrombophlebitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients are encouraged to ambulate following surgery. The patient should make an effort to walk for 5 to 10 minutes each hour during waking hours. The patient should avoid prolonged standing and sitting. When not walking, the patient is encouraged to elevate the leg above the level of the heart",
"   </p>",
"   <p>",
"    Bruising along the tract of excised veins is common, and can take up to six weeks following surgery to resolve. Postoperative compression may help to limit bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Compression stockings'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    The operative dressings including the elastic",
"    <span class=\"nowrap\">",
"     bandages/stockings",
"    </span>",
"    are maintained for several days. The patient may reinforce any small areas of bleeding that occur through the dressing, but should call their surgeon if excessive bleeding occurs. Once the operative dressing is removed, elastic stockings are worn during the day and removed at night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H7#H7\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Graduated compression stockings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal activities can be resumed when tolerated, usually within three to four days. Time off work varies between one and three weeks depending upon the patient's job requirements and the magnitude of the operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     When to call the surgeon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should call their surgeon to be seen immediately if they notice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent bleeding through the bandages after reinforcement, or excessive or sudden bleeding that saturates the bandage.",
"     </li>",
"     <li>",
"      Tingling, coolness, or discoloration of the toes of the treated extremity. The elastic",
"      <span class=\"nowrap\">",
"       bandages/stockings",
"      </span>",
"      may be too tight and need to be removed.",
"     </li>",
"     <li>",
"      Swelling or excessive pain not relieved with the prescribed pain medications because this may be a symptom of deep vein thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of vein ablation surgery are bruising and hematoma formation. Other complications include wound infection, hyperpigmentation, telangiectatic matting, phlebitis (superficial or deep) and cutaneous nerve injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small hematomas along the course of the excised vein are common, but large hematomas should prompt examination by the treating surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infection rates following surgical vein excision are often greater than would be expected for clean surgery. Incidences up to 16 percent have been reported and may be related to the need for groin dissection, a propensity for hematoma formation along the course of excised veins, and the presence of venous ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Saphenous or sural nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saphenous nerve injury occurs in up to 10 percent of patients following saphenous vein removal with the highest incidence associated with saphenous vein removal to the level of the ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. Care should be taken during the procedure to avoid injury to these nerves, which leads to an unpleasant sensory abnormality along the medial (saphenous nerve) or lateral (sural nerve) leg. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Superficial thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial thrombophlebitis is common in venous tributaries along the course of the excised vein and is usually self-limited. The treatment is conservative (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis following saphenous removal is a complication of the dissection of venous structures in the groin. It may also result from compression by significant groin hematoma. Deep vein thrombosis should be suspected in any patient who has excessive lower extremity swelling or pain following open surgical vein excision. Deep vein thrombus is diagnosed and managed according to standard protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450925728\">",
"    <span class=\"h2\">",
"     Lymphocele and lymph leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients may experience persistent lymph drainage from phlebectomy incisions. In most cases, lymph drainage stops spontaneously, but rarely it may become necessary to surgically ligate persistent lymph leaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy for chronic venous disease is the standard to which the minimally invasive therapies have been compared [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Surgical intervention for venous disease improves symptoms, and the majority of patients are generally satisfied with surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of surgery for patients with severe varicose veins and reflux compared with conservative management was evaluated in a randomized trial of 250 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgery improved outcomes (quality of life, symptomatic relief, and anatomic extent) and was cost-effective at two years, with a projected cost benefit out to 10 years.",
"   </p>",
"   <p>",
"    However, in randomized trials, minimally invasive techniques for saphenous ablation appear to be as effective as saphenous ligation and removal for the management of reflux, but offer significant advantages such as a lack of a groin incision, less postoperative pain, and quicker recovery times [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/35-45\">",
"     35-45",
"    </a>",
"    ]. For the majority of patients, chronic venous disease can be effectively managed using minimally invasive techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Varicose vein recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the treated veins are removed, the risk of recanalization with open surgery is zero; however, enlargement of other veins in the extremity can occur over time. Surgical techniques are associated with varicose vein recurrence rates between 20 and 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/34,46-48\">",
"     34,46-48",
"    </a>",
"    ]. The cause of recurrences may include surgical technique, progression of the underlying disease, or neovascularization.",
"   </p>",
"   <p>",
"    In randomized trials, vein ligation plus removal has lower recurrence rates compared with vein ligation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/15,49\">",
"     15,49",
"    </a>",
"    ]. Of the open surgical techniques, vein removal is the preferred technique for patients with saphenofemoral reflux and varicose veins in the great saphenous distribution. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'High saphenous ligation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Saphenous vein inversion and removal'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ulcer healing and recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial vein excision reduces reflux in the deep veins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], and although it does not speed the rate of ulcer healing, vein excision significantly reduces ulcer recurrence compared with compression therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. The ESCHAR trial randomly assigned 500 patients with open or recently healed ulcers, and evidence for reflux, to compression therapy alone (multilayer) or compression therapy plus surgery (saphenous ligation or removal and non-saphenous vein excision) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/54\">",
"     54",
"    </a>",
"    ]. For patients with ulceration, healing rates at 24 weeks with compression therapy plus surgery were similar to those with compression therapy alone, but recurrence rates at 12 months were significantly lower in the surgical compared with nonsurgical groups (28 versus 12 percent). Four-year follow-up data from the ESCHAR trial confirmed the long-term benefit of surgery plus compression over compression alone for the reduction of venous ulcer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21977/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=see_link\">",
"       \"Patient information: Vein ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical methods of vein ablation, particularly saphenous ablation, have been supplanted by minimally invasive methods, but remain the standard to which the minimally invasive techniques are compared. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical therapy is most commonly used for the management of large varicose veins (&gt;1.5 cm), complications of varicose veins (eg, varicose vein hemorrhage, recurrent phlebitis). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical techniques involve ligation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      removal of veins through multiple incisions. Specific techniques include saphenous vein inversion and removal, high ligation of the saphenous vein, ambulatory phlebectomy, transilluminated phlebectomy, conservative venous ligation (CHIVA), and perforator ligation. (See",
"      <a class=\"local\" href=\"#H57470085\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compression therapy (eg, ACE wraps, compression stockings) is used to limit bruising, hematoma formation, and swelling in the postoperative period. Compression stockings are maintained until bruising has resolved. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Postoperative instructions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications following varicose vein surgery include bruising and hematoma formation, infection, nerve injury, phlebitis (superficial or deep), and lymphatic leak. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venous ulcer healing rates are not significantly improved following surgical intervention; however, ulcer recurrence is reduced compared with compression therapy alone. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/1\">",
"      Aremu MA, Mahendran B, Butcher W, et al. Prospective randomized controlled trial: conventional versus powered phlebectomy. J Vasc Surg 2004; 39:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/2\">",
"      Kirby JP, Mazuski JE. Prevention of surgical site infection. Surg Clin North Am 2009; 89:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/3\">",
"      Mekako AI, Chetter IC, Coughlin PA, et al. Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in varicose vein surgery. Br J Surg 2010; 97:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/4\">",
"      Wilson AP, Treasure T, Sturridge MF, Gr&uuml;neberg RN. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet 1986; 1:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/5\">",
"      Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011; 53:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/6\">",
"      Biswas S, Clark A, Shields DA. Randomised clinical trial of the duration of compression therapy after varicose vein surgery. Eur J Vasc Endovasc Surg 2007; 33:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/7\">",
"      Houtermans-Auckel JP, van Rossum E, Teijink JA, et al. To wear or not to wear compression stockings after varicose vein stripping: a randomised controlled trial. Eur J Vasc Endovasc Surg 2009; 38:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/8\">",
"      Pittaluga S, Chastaner S. Value of Postoperative Compression After Surgical Treatment of Varicose. J Vasc Surg 2012; 55:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/9\">",
"      Zharov VP, Ferguson S, Eidt JF, et al. Infrared imaging of subcutaneous veins. Lasers Surg Med 2004; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/10\">",
"      Thompson JF, Royle GT, Farrands PA, et al. Varicose vein surgery using a pneumatic tourniquet: reduced blood loss and improved cosmesis. Ann R Coll Surg Engl 1990; 72:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/11\">",
"      Robinson J, Macierewicz J, Beard JD. Using the Boazul cuff to reduce blood loss in varicose vein surgery. Eur J Vasc Endovasc Surg 2000; 20:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/12\">",
"      Sykes TC, Brookes P, Hickey NC. A prospective randomised trial of tourniquet in varicose vein surgery. Ann R Coll Surg Engl 2000; 82:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/13\">",
"      Rigby KA, Palfreyman SJ, Beverley C, Michaels JA. Surgery for varicose veins: use of tourniquet. Cochrane Database Syst Rev 2002; :CD001486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/14\">",
"      Menyhei G, Gyevn&aacute;r Z, Arat&oacute; E, et al. Conventional stripping versus cryostripping: a prospective randomised trial to compare improvement in quality of life and complications. Eur J Vasc Endovasc Surg 2008; 35:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/15\">",
"      Dwerryhouse S, Davies B, Harradine K, Earnshaw JJ. Stripping the long saphenous vein reduces the rate of reoperation for recurrent varicose veins: five-year results of a randomized trial. J Vasc Surg 1999; 29:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/16\">",
"      Davidovi L, Kosti D, Lotina S, Cinara I. [Indications for surgical treatment of acute superficial thrombophlebitis]. Srp Arh Celok Lek 1990; 118:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/17\">",
"      Crane J, Cheshire N. Recent developments in vascular surgery. BMJ 2003; 327:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/18\">",
"      Luebke T, Brunkwall J. Meta-analysis of transilluminated powered phlebectomy for superficial varicosities. J Cardiovasc Surg (Torino) 2008; 49:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/19\">",
"      Scav&eacute;e V. Transilluminated powered phlebectomy: not enough advantages? Review of the literature. Eur J Vasc Endovasc Surg 2006; 31:316.",
"     </a>",
"    </li>",
"    <li>",
"     Franceschi, C. Th&eacute;orie et practique de la cure conservatrice et h&eacute;modynamique de l'insuffisance veineuse en ambulatoire. Pr&eacute;cyy-sous-thil, France: Edition de l'Araman&ccedil;on, 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/21\">",
"      Criado, E. Haemodynamic surgery for varicose veins: rationale, and anatomic and haemodynamic basis. Phlebology 2003; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/22\">",
"      Par&eacute;s JO, Juan J, Tellez R, et al. Varicose vein surgery: stripping versus the CHIVA method: a randomized controlled trial. Ann Surg 2010; 251:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/23\">",
"      Gloviczki P, Bergan JJ, Menawat SS, et al. Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American registry. J Vasc Surg 1997; 25:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/24\">",
"      Hirsemann S, Sohr D, Gastmeier K, Gastmeier P. Risk factors for surgical site infections in a free-standing outpatient setting. Am J Infect Control 2005; 33:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/25\">",
"      Corder AP, Schache DJ, Farquharson SM, Tristram S. Wound infection following high saphenous ligation. A trial comparing two skin closure techniques: subcuticular polyglycolic acid and interrupted monofilament nylon mattress sutures. J R Coll Surg Edinb 1991; 36:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/26\">",
"      Rigby KA, Palfreyman SJ, Beverley C, Michaels JA. Surgery versus sclerotherapy for the treatment of varicose veins. Cochrane Database Syst Rev 2004; :CD004980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/27\">",
"      Fischer R, Linde N, Duff C, et al. Late recurrent saphenofemoral junction reflux after ligation and stripping of the greater saphenous vein. J Vasc Surg 2001; 34:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/28\">",
"      Ratcliffe J, Brazier JE, Campbell WB, et al. Cost-effectiveness analysis of surgery versus conservative treatment for uncomplicated varicose veins in a randomized clinical trial. Br J Surg 2006; 93:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/29\">",
"      Winterborn RJ, Foy C, Earnshaw JJ. Causes of varicose vein recurrence: late results of a randomized controlled trial of stripping the long saphenous vein. J Vasc Surg 2004; 40:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/30\">",
"      Baker DM, Turnbull NB, Pearson JC, Makin GS. How successful is varicose vein surgery? A patient outcome study following varicose vein surgery using the SF-36 Health Assessment Questionnaire. Eur J Vasc Endovasc Surg 1995; 9:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/31\">",
"      MacKenzie RK, Paisley A, Allan PL, et al. The effect of long saphenous vein stripping on quality of life. J Vasc Surg 2002; 35:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/32\">",
"      Garratt AM, Macdonald LM, Ruta DA, et al. Towards measurement of outcome for patients with varicose veins. Qual Health Care 1993; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/33\">",
"      Smith JJ, Garratt AM, Guest M, et al. Evaluating and improving health-related quality of life in patients with varicose veins. J Vasc Surg 1999; 30:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/34\">",
"      Michaels JA, Campbell WB, Brazier JE, et al. Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). Health Technol Assess 2006; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/35\">",
"      Negl&eacute;n P, Einarsson E, Ekl&ouml;f B. The functional long-term value of different types of treatment for saphenous vein incompetence. J Cardiovasc Surg (Torino) 1993; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/36\">",
"      Belcaro G, Cesarone MR, Di Renzo A, et al. Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). Angiology 2003; 54:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/37\">",
"      Belcaro G, Nicolaides AN, Ricci A, et al. Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results. Angiology 2000; 51:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/38\">",
"      Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Eur J Vasc Endovasc Surg 2005; 29:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/39\">",
"      Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg 2007; 46:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/40\">",
"      Kalteis M, Berger I, Messie-Werndl S, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study. J Vasc Surg 2008; 47:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/41\">",
"      Almeida JI, Kaufman J, G&ouml;ckeritz O, et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study). J Vasc Interv Radiol 2009; 20:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/42\">",
"      Bacon JL, Dinneen AJ, Marsh P, et al. Five-year results of incompetent perforator vein closure using TRans-Luminal Occlusion of Perforator. Phlebology 2009; 24:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/43\">",
"      Masuda EM, Kessler DM, Lurie F, et al. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. J Vasc Surg 2006; 43:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/44\">",
"      Luebke T, Brunkwall J. Meta-analysis of subfascial endoscopic perforator vein surgery (SEPS) for chronic venous insufficiency. Phlebology 2009; 24:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/45\">",
"      Viarengo LM, Pot&eacute;rio-Filho J, Pot&eacute;rio GM, et al. Endovenous laser treatment for varicose veins in patients with active ulcers: measurement of intravenous and perivenous temperatures during the procedure. Dermatol Surg 2007; 33:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/46\">",
"      Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg 1995; 21:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/47\">",
"      Darke SG. The morphology of recurrent varicose veins. Eur J Vasc Surg 1992; 6:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/48\">",
"      Sarin S, Scurr JH, Coleridge Smith PD. Assessment of stripping the long saphenous vein in the treatment of primary varicose veins. Br J Surg 1992; 79:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/49\">",
"      Sarin S, Scurr JH, Coleridge Smith PD. Stripping of the long saphenous vein in the treatment of primary varicose veins. Br J Surg 1994; 81:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/50\">",
"      Walsh JC, Bergan JJ, Beeman S, Comer TP. Femoral venous reflux abolished by greater saphenous vein stripping. Ann Vasc Surg 1994; 8:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/51\">",
"      Sales CM, Bilof ML, Petrillo KA, Luka NL. Correction of lower extremity deep venous incompetence by ablation of superficial venous reflux. Ann Vasc Surg 1996; 10:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/52\">",
"      Adam DJ, Bello M, Hartshorne T, London NJ. Role of superficial venous surgery in patients with combined superficial and segmental deep venous reflux. Eur J Vasc Endovasc Surg 2003; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/53\">",
"      O'Donnell TF Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/54\">",
"      Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004; 363:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/55\">",
"      Barwell JR, Taylor M, Deacon J, et al. Surgical correction of isolated superficial venous reflux reduces long-term recurrence rate in chronic venous leg ulcers. Eur J Vasc Endovasc Surg 2000; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/56\">",
"      Zamboni P, Cisno C, Marchetti F, et al. Minimally invasive surgical management of primary venous ulcers vs. compression treatment: a randomized clinical trial. Eur J Vasc Endovasc Surg 2003; 25:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21977/abstract/57\">",
"      Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 2007; 335:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8182 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21977=[""].join("\n");
var outline_f21_29_21977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Venous anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Saphenous nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sural nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Compression stockings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vein mapping/marking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57470073\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57470085\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57470044\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Saphenous vein inversion and removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      High saphenous ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ambulatory phlebectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450925705\">",
"      Transilluminated powered phlebectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57470051\">",
"      Conservative venous ligation (CHIVA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Perforator ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Surgical perforator ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POSTOPERATIVE INSTRUCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      When to call the surgeon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Saphenous or sural nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Superficial thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450925728\">",
"      Lymphocele and lymph leak",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Varicose vein recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ulcer healing and recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8182|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/46/36579\" title=\"figure 1A\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42671\" title=\"figure 1B\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/56/43906\" title=\"figure 2\">",
"      Deep veins of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/42/37547\" title=\"table 1\">",
"      Compression stockings in chronic venous disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30250?source=related_link\">",
"      Endovenous laser ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=related_link\">",
"      Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=related_link\">",
"      Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=related_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=related_link\">",
"      Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_29_21978="Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance";
var content_f21_29_21978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Carlton C Barnett, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Eddie K Abdalla, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/29/21978/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/29/21978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H969399451\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease, which may be related to infection with hepatitis B virus (HBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C virus (HCV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Curative partial hepatectomy is the optimal treatment for HCC, but many patients are not eligible for resection because of extrahepatic disease spread, the anatomical constraints of the intrahepatic tumor, or poor underlying liver function, as reflected by the Child-Pugh classification (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) or the Model for End-stage Liver Disease (MELD) score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link&amp;anchor=H12#H12\">",
"     \"Assessing surgical risk in patients with liver disease\", section on 'MELD score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even after a potentially curative resection, local recurrence rates are high. This has led to efforts to develop neoadjuvant and adjuvant therapy approaches to improve outcomes.",
"   </p>",
"   <p>",
"    This topic will cover prognosis and neoadjuvant and adjuvant therapy for potentially resectable hepatocellular cancer, as well as posttreatment surveillance. The clinical manifestations and diagnosis of HCC, preoperative evaluation and surgical management, nonsurgical options for local ablation, role of liver transplantation, treatment of advanced disease, and an overview of treatment approaches to HCC are presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"       \"Liver transplantation for hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39898?source=see_link\">",
"       \"Systemic treatment for advanced hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"       \"Overview of treatment approaches for hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969400077\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, which is most often related to infection with hepatitis B virus (HBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C virus (HCV). Furthermore, patients who undergo therapy for HCC are at high risk not only for recurrent disease but also for progression to liver failure. It is important that patients have proper monitoring and assessment of their underlying liver disease, which may have a major impact on longer term survival. Comprehensive care for patients with cirrhosis includes antiviral therapy for HBV and HCV, immunization against hepatitis A and HBV (if indicated), and endoscopic screening, surveillance, and treatment for varices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969400084\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation for resection of HCC focuses on two main issues: the likelihood of disease being confined to the liver, and whether the anatomical constraints of the intrahepatic tumor and underlying liver function will permit resection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic delineation of tumor extent is best achieved with dynamic multiphase CT (in which nonenhanced, hepatic arterial phase and portal venous phase are assessed separately) or MRI scanning. According to the current",
"      <span class=\"nowrap\">",
"       TNM/UICC",
"      </span>",
"      staging system for HCC (",
"      <a class=\"graphic graphic_table graphicRef63333 \" href=\"UTD.htm?1/45/1757\">",
"       table 2",
"      </a>",
"      ), most consider stages IIIB, IIIC, and stage IV disease to be categorically incurable by resection. These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum, and nodal as well as distant metastases. However, hepatic resection for stages IIIB, IIIC, and IVA disease may be considered in a center of excellence because clinical benefits and long-term survival can be achieved in a properly selected, though admittedly small, minority of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Determining the extent of tumor involvement'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A chest CT is recommended to complete the staging evaluation. Although characterized in few reports, the recognized sites of metastatic spread of HCC are lung, bone, peritoneum, and adrenals. These sites of disease may be demonstrated by standard imaging techniques, but peritoneal disease is frequently missed. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Patterns of metastatic spread'",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      Less than 10 percent of HCC spontaneously rupture. Although these patients have a high likelihood of peritoneal seeding and usually a poor outcome from resection, this is not inevitable. If bleeding can be controlled, a formal staging evaluation should be undertaken, followed by laparoscopic exploration and a subsequent attempt at resection, if feasible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Determining the extent of tumor involvement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients undergoing potentially curative partial hepatectomy for HCC, most perioperative deaths, particularly following major hepatectomy, are due to postoperative liver failure. The presence of cirrhosis is the most important predictor of postresection liver failure and death. There are several strategies, including careful selection, tailoring the extent of resection to liver function, and preoperative embolization that can mitigate these risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H12#H12\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Postoperative morbidity and mortality'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Eligible candidates for resection must have a suitable tumor location, adequate liver reserve, and a sufficient liver remnant as assessed by clinical and biochemical measures, and in the case of major hepatectomy, by hepatic volumetry. As a general rule, for patients who have severe or uncompensated cirrhosis, techniques such as preoperative portal vein embolization (PVE) can initiate hypertrophy of the anticipated future liver remnant to enable a major resection that would otherwise leave a remnant liver insufficient to support life following partial hepatectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H1061867819#H1061867819\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Portal vein embolization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401849\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide variability in outcomes after resection for HCC, attributable to both tumor-related factors and the underlying liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/1-19\">",
"     1-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term overall survival rates of &ge;40 percent can be achieved with limited hepatic resections for small tumors (&lt;5 cm) in patients with Child-Pugh class A cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/3,8,12\">",
"     3,8,12",
"    </a>",
"    ]. The best outcomes are reported in carefully selected patients who have solitary lesions without intrahepatic metastasis or vascular invasion (gross or microscopic invasion of branches of the portal or hepatic veins), tumor diameter &le;5 cm, and a negative surgical margin of &gt;1 cm; five-year survival rates are as high as 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/2,11,13,14,17,20\">",
"     2,11,13,14,17,20",
"    </a>",
"    ]. Recent series demonstrate prolonged survival for more advanced HCC with proper patient selection despite major hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, studies with lower long-term survival rates usually include populations of patients with severe cirrhosis (Child-Pugh class B or C, (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    )) or tumors greater than 8 cm in diameter, which require resection of more hepatic parenchyma. These patients have higher operative morbidity and mortality, and their intrinsic liver disease is a major contributor to reduced long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H969401863\">",
"     'Underlying liver dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several staging systems have been developed to prognostically stratify outcomes from treatment of HCC. Some, like the TNM staging system of the American Joint Committee on Cancer (AJCC), are based entirely upon pathologic disease extent (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"UTD.htm?1/45/1757\">",
"     table 2",
"    </a>",
"    ), while others, such as that of the Cancer of the Liver Italian Program (CLIP, (",
"    <a class=\"graphic graphic_table graphicRef69726 \" href=\"UTD.htm?7/51/7996\">",
"     table 3",
"    </a>",
"    )), take underlying liver function into account [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. There is ongoing debate as to which staging system is optimal for use in patients who do not undergo hepatic resection. Among hepatologists, the Barcelona Clinic Liver Cancer (BCLC) staging classification (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"UTD.htm?11/36/11855\">",
"     algorithm 1",
"    </a>",
"    ), is the most widely used staging system other than the AJCC staging classification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link&amp;anchor=H8#H8\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\", section on 'Choice of staging system'",
"    </a>",
"    .) Specific prognostic factors in patients undergoing potentially curative resection are summarized below. A more general discussion about prognostic factors in HCC is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link&amp;anchor=H9#H9\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\", section on 'Other factors influencing survival'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401856\">",
"    <span class=\"h2\">",
"     Tumor-related prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important tumor-related prognostic factors in patients undergoing potentially curative resection of HCC are the presence and degree of vascular invasion, tumor number and size, and surgical margin status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross or microscopic invasion of branches of the portal or hepatic veins is associated with a lower probability of survival following resection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/2,27\">",
"       2,27",
"      </a>",
"      ]. In one report, there were no three-year survivors among patients with vascular invasion, compared with a 32 percent five-year survival rate in those without vascular invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor size is an important prognostic factor. Both intrahepatic and extrahepatic spread of HCC are more common with tumors &gt;5 cm, particularly when associated with venous invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/2,12,28-32\">",
"       2,12,28-32",
"      </a>",
"      ]. In a report that compared 1000 patients with tumors &le;5 cm and 1366 patients having tumors &gt;5 cm, all of whom underwent hepatectomy over the same period, five-year survival rates were significantly better for patients with smaller tumors (63 versus 37 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/32\">",
"       32",
"      </a>",
"      ]. Nevertheless, several series indicate five year survival rates ranging from 19 to 27 percent in selected patients undergoing resection for single HCC &ge;10 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/22,33,34\">",
"       22,33,34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although increasing tumor size is associated with increased risk for vascular invasion, large, solitary tumors without vascular invasion have the same prognosis as small solitary tumors without vascular invasion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Determining the extent of tumor involvement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The importance of wide resection margins is debated. In a study of 225 patients who underwent resection for HCC, three-year survival was significantly better when a &gt;1 cm tumor-free margin was achieved (77 versus 21 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/6\">",
"       6",
"      </a>",
"      ]. However, larger series suggest that a negative margin of less than 1 cm is acceptable [",
"      <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tumor-related poor prognostic indicators in patients undergoing potentially curative hepatectomy are absence of a tumor capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/15\">",
"     15",
"    </a>",
"    ], high preoperative alpha fetoprotein (AFP) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/36-40\">",
"     36-40",
"    </a>",
"    ], and poor histologic grade of differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Serum markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401863\">",
"    <span class=\"h2\">",
"     Underlying liver dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative liver dysfunction and cirrhosis are important negative prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. In one series of 295 patients undergoing resection of HCC, the four-year survival was more than twofold higher for noncirrhotic compared to cirrhotic patients (81 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/12\">",
"     12",
"    </a>",
"    ]. This difference in outcome may be related in part to the higher frequency of multicentric HCC in cirrhotic patients.",
"   </p>",
"   <p>",
"    As a general rule, the severity of cirrhosis, rather than the presence of the cancer, limits long-term survival in cirrhotic patients with a small, early stage HCC. The presence of cirrhosis contributes to the development of second primary HCCs and a persisting risk of HCC-related death beyond five years. These principles were illustrated in one multi-institutional series of 591 patients undergoing resection of HCC, of whom 145 survived longer than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/31\">",
"     31",
"    </a>",
"    ]. While the status of surgical margins, type of resection, preoperative AFP level, and the presence of multiple tumors or microscopic vascular invasion were important predictors of five-year survival, they had no bearing on survival beyond five years. However, patients who survived for at least five years had significantly longer survival and cancer-specific survival beyond that point if they had normal underlying liver or minimal periportal fibrosis, rather than underlying moderate or severe cirrhosis.",
"   </p>",
"   <p>",
"    In Western countries where HCC is less frequently associated with chronic HBV infection or cirrhosis, five-year survival rates are better (27 to 49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/3,7,42\">",
"     3,7,42",
"    </a>",
"    ] than they are in locations where HBV is endemic and incidence rates of HCC are high (11 percent or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/5,23,43,44\">",
"     5,23,43,44",
"    </a>",
"    ]. This is likely due to diagnosis at earlier stages in Western countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link&amp;anchor=H14#H14\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\", section on 'Hepatitis B and C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link&amp;anchor=H10#H10\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\", section on 'High versus low-incidence regions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with cirrhosis related to HBV infection, active hepatitis is also a poor prognostic factor. This was illustrated in a report comparing surgical outcomes in 146 patients with resected HCC and HBV-related Child-Pugh class A or B cirrhosis, with those of 155 noncirrhotic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/30\">",
"     30",
"    </a>",
"    ]. Although the prognosis after resection of tumors &lt;5 cm in patients with compensated HBV-related cirrhosis was comparable to that of noncirrhotic patients, the outcome was less favorable in those with underlying active hepatitis, as indicated by a preoperative serum aspartate aminotransferase level &gt;100 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    (median survival 10 versus 51 months for those with serum aspartate aminotransferase &gt;100 versus &le;100 international",
"    <span class=\"nowrap\">",
"     units/L,",
"    </span>",
"    respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401870\">",
"    <span class=\"h2\">",
"     Patterns of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of recurrences are intrahepatic, and may reflect local recurrence, or a new second primary lesion. Several effective treatment modalities can provide disease control including repeat hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], transarterial embolization or chemoembolization, radiofrequency ablation, and liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fewer than 20 percent of disease recurrences have an extrahepatic component, which may present simultaneously with or develop after an intrahepatic recurrence, or represent the only site of disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with extrahepatic spread have a poor prognosis overall, and the benefit of systemic therapy is modest, at best. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39898?source=see_link\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401877\">",
"    <span class=\"h1\">",
"     NEOADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite potentially curative surgery, local recurrence develops in the majority of patients. It is believed that recurrences arise not because of inadequate surgical resection, but because of preexisting clinically occult microscopic tumor foci, thus providing the impetus to evaluate neoadjuvant therapies to eradicate this disease prior to definitive resection.",
"   </p>",
"   <p>",
"    Several types of therapy have been evaluated, including regional approaches (transarterial chemoembolization [TACE] [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/49-56\">",
"     49-56",
"    </a>",
"    ], hepatic artery infusion of radiolabeled lipiodol [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/57\">",
"     57",
"    </a>",
"    ], and regional irradiation with or without chemotherapy or TACE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]) and systemic chemoimmunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many of these therapies can decrease the size of previously unresectable tumors, this has not translated into a survival benefit in most studies. Furthermore, the small size of many studies, the relative paucity of randomized controlled trials, and the heterogeneity in the patient populations under study limit the ability to interpret and compare data.",
"   </p>",
"   <p>",
"    Furthermore, a number of uncontrolled series and at least one controlled trial have suggested that TACE used prior to an attempt at resection is associated with",
"    <strong>",
"     worse survival",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/51-54,56\">",
"     51-54,56",
"    </a>",
"    ]. In a controlled trial, 52 patients with resectable large HCC were randomly assigned to preoperative TACE (one to five courses) or surgery without delay [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients randomized to TACE had a slightly longer operative time and a higher rate of concomitant resection of adjacent organs. Despite a similar disease-free survival in the two groups, the incidence of extrahepatic cancer was higher in those who had been treated with TACE (57 versus 23 percent), and the actuarial survival rate was significantly worse in this group. The delay in surgical treatment may have contributed to this detrimental impact on survival.",
"   </p>",
"   <p>",
"    For all of these reasons, neoadjuvant therapy cannot be considered a standard approach to therapy.",
"   </p>",
"   <p>",
"    On the other hand, TACE followed by portal vein embolization (PVE) has been proposed as an optimal approach to prepare for major hepatectomy. At least some data suggest better tumor control, very low surgical morbidity and mortality, and favorable long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/21,61-63\">",
"     21,61-63",
"    </a>",
"    ]. However, whether these outcomes are better than can be achieved by preoperative PVE alone is not known, and this has not yet been adopted as a standard approach. The benefits of PVE, and the use of TACE, including its use in patients awaiting orthotopic liver transplantation for HCC (termed &ldquo;bridging therapy&rdquo;), is discussed in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H1061867819#H1061867819\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Portal vein embolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=see_link&amp;anchor=H1248650335#H1248650335\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Prior to liver transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link&amp;anchor=H11#H11\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Chemoembolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401884\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high recurrence rate following curative resection for HCC has prompted a search for effective postoperative (&ldquo;adjuvant&rdquo;) therapies. In contrast to other solid tumors, the goals of postoperative therapy for HCC are twofold: eliminating residual neoplastic cells (the traditional concept of systemic adjuvant therapy for disease like breast and colon cancer) and prevention of second primary HCCs (ie, secondary chemoprevention).",
"   </p>",
"   <p>",
"    Many trials have explored several different adjuvant strategies including systemic and intraarterial chemotherapy, intraarterial radiolabeled lipiodol, TACE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], acyclic retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/16,68-76\">",
"     16,68-76",
"    </a>",
"    ], adoptive immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/77\">",
"     77",
"    </a>",
"    ], and vaccination with autologous tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/78\">",
"     78",
"    </a>",
"    ]. Although some of these trials demonstrate a significant survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/64,66,68,69,79-81\">",
"     64,66,68,69,79-81",
"    </a>",
"    ], a conclusive role for adjuvant systemic or intraarterial adjuvant treatment after hepatic resection has not yet been established, and no form of therapy should be considered standard of care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401891\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative lack of efficacy of standard chemotherapeutic agents for HCC has hampered the development of successful adjuvant chemotherapy regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39898?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Systemic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of adjuvant locoregional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic chemotherapy was addressed in a meta-analysis of 108 patients enrolled in three randomized trials (hepatic arterial infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    followed by prolonged oral tegafur, hepatic intraarterial epirubicin followed by intravenous (IV) epirubicin and then an oral fluoropyrimidine, or IV epirubicin) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/82\">",
"     82",
"    </a>",
"    ]. There was no overall improvement in disease-free or overall survival compared with resection alone and an",
"    <strong>",
"     increase",
"    </strong>",
"    in mortality in patients who had biopsy-proven cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3734180\">",
"    <span class=\"h2\">",
"     Radiolabeled lipiodol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another locoregional approach involves the intraarterial infusion of iodine-131 (131I)-labeled lipiodol. Lipiodol (Laboratoire Guerbet, France) is a stable fatty acid ethyl ester derived from poppy seed oil that is retained within HCC after intraarterial injection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/83\">",
"     83",
"    </a>",
"    ]. In a trial from Hong Kong in which 43 patients with HCC (mostly related to chronic HBV infection) were randomly assigned to a single dose of 131I-lipiodol or placebo following curative resection, treatment was associated with significantly fewer tumor recurrences (48 versus 64 percent) and significantly higher rates of five-year disease-free and overall survival (67 versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/80,84\">",
"     80,84",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Although these findings are promising, independent confirmation is necessary; such a trial, involving 100 patients, has completed accrual and is awaiting data maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/85\">",
"     85",
"    </a>",
"    ]. This approach also needs further evaluation in patients with HCC related to different underlying diseases (such as hepatitis C virus infection [HCV]), which may have different tumor biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3734030\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    (Nexavar) is a multitargeted orally active small molecule tyrosine kinase inhibitor that inhibits Raf kinase and also blocks the intracellular portion of the VEGFR. The multicenter placebo-controlled European SHARP trial established sorafenib monotherapy as a reference standard systemic treatment for advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The benefit of adjuvant sorafenib following complete resection of HCC has not been established. An international phase III trial of sorafenib versus placebo following potentially curative resection or local ablation (the STORM trial) has been completed and is awaiting data maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401907\">",
"    <span class=\"h2\">",
"     Acyclic retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peretinoin (polyprenoic acid), an acyclic retinoid, has also been studied for preventing tumor recurrence. In a small randomized placebo-controlled phase II trial of 89 patients with HCC who were free of disease following surgery or percutaneous ethanol injection, peretinoin significantly reduced the incidence of recurrent or new hepatomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/87\">",
"     87",
"    </a>",
"    ] and improved overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these results could not be confirmed in a larger prospective double-blind randomized trial of adjuvant peretinoin (at two different dose levels, 600 or 300 mg daily) versus placebo following either resection or local tumor ablation for HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/67\">",
"     67",
"    </a>",
"    ]. In a preliminary report at a median follow-up of 2.5 years, there was no difference in cumulative relapse-free survival up to two years postresection with either dose of peretinoin, although there was a suggestion of long-term benefit beyond two years with high-dose therapy. The drug is not available for use anywhere in the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969401914\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HBV-related HCC, higher viral load (serum HBV DNA of &gt;106",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    has been associated with higher rates of recurrence after resection, particularly late recurrence (which is more likely to represent a de novo second primary tumor rather than a metastasis from the primary HCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. These data suggest that antiviral therapy to suppress HBV replication might reduce the rate of HCC recurrence and improve outcomes. Antiviral therapy may also diminish the risk of postoperative liver failure in patients with high viral load and active inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82761805\">",
"    <span class=\"h3\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon suppresses the replication of hepatitis B and C virus. The benefit of postoperative interferon alfa (IFNa, and in one case, interferon-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/70\">",
"     70",
"    </a>",
"    ]) has been addressed in several controlled trials, most conducted in Asian populations with predominantly hepatitis virus-associated HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/16,68-76\">",
"     16,68-76",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    One of the largest trials, from China, randomly assigned 236 patients with HBV-related HCC to IFNa (3 MIU via intramuscular injection twice weekly for two weeks, then 5 MIU three times weekly for 18 months) versus no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/69\">",
"     69",
"    </a>",
"    ]. Although the two groups had a similar number of recurrences overall (67 versus 71 with IFNa and control, respectively), IFNa was associated with a significantly longer survival duration (median 64 versus 39 months, respectively).",
"    <br/>",
"    <br/>",
"    A meta-analysis of this and five other trials of postoperative IFN after curative resection of HCC in patients with viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/70-72,75\">",
"     70-72,75",
"    </a>",
"    ] concluded that adjuvant IFNa significantly decreased early (within two years of surgery) mortality after curative resection for HCC (pooled risk ratio [RR] 0.65, 95% CI 0.52-0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/81\">",
"     81",
"    </a>",
"    ]. The effect on tumor recurrence was less pronounced but still significant (RR 0.86, 95% CI 0.76-0.97). The drug had to be discontinued because of side effects in 8 to 20 percent of treated patients.",
"    <br/>",
"    <br/>",
"    Most of these trials lack data on long-term outcomes. In one of the only reported trials with long-term follow-up (median 63.8 months), individuals who were randomly assigned to one year of adjuvant IFN after potentially curative resection did not have a significantly lower risk of disease recurrence as compared with those in the observation alone control group (median relapse-free survival 42 versus 49 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the paucity of information on late outcomes (and persisting questions as to whether disease recurrence is being delayed or truly prevented), the fact that most patients in these trials had HBV rather than HCV infection, the prominence of side effects with IFN, and the small sample sizes overall, these data are insufficient to conclude that adjuvant IFNa should be considered a standard approach following complete resection of HCC. These results await confirmation in larger controlled trials, which will probably focus on the long-acting pegylated forms of IFN.",
"    <br/>",
"    <br/>",
"    A preliminary report suggests an association between low levels of tumor expression of specific microRNAs (miRNAs), small noncoding RNAs that modulate the expression of genes at the posttranscriptional level, and both survival and response to postoperative IFN in patients with resected HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/90\">",
"     90",
"    </a>",
"    ]. In a retrospective analysis of two prospective randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/69,71\">",
"     69,71",
"    </a>",
"    ], only patients with reduced expression of miR-26 had a favorable response to adjuvant IFN. Further work in this area is needed. Because of the side effects of interferon and the need for maintained viral suppression,",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogs are preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82761845\">",
"    <span class=\"h3\">",
"     Nucleoside/nucleotide analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials examining the benefit of antiviral therapy with nucleoside analogs after resection of HCC. An overview of the use of nucleoside analogs in patients with hepatitis B virus infection (HBV) is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between nucleoside analog use and outcomes after resection of HCC was addressed in a nationwide cohort study from Taiwan, which included 4569 patients with HBV-related HCC who underwent potentially curative resection between October 2003 and September 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/91\">",
"     91",
"    </a>",
"    ]. The risk of a first tumor recurrence was compared among patients who not taking nucleoside analogs (n = 4051) and those taking nucleoside analogs (n = 518, mean duration of use 1.45 years).",
"   </p>",
"   <p>",
"    At a relatively short median follow-up duration (2.18 years for the untreated, and 2.64 years for the treated cohort), antiviral treatment was associated with a significantly lower risk of HCC recurrence (six-year cumulative incidence 46 versus 55 percent) and significantly lower overall mortality (10.6 versus 28.3 percent). Unfortunately, the study has many limitations that limit interpretation of these results. Data are not available from this database series on the completeness of resection, recurrences were only counted if they required rehospitalization and administration of HCC treatment after the index admission, and there was a potential for survivor bias. Follow-up of the untreated cohort began on the first day after the index admission while follow-up of the treated cohort began on the day of the first prescription of the nucleoside analog, which occurred a median of 0.66 years, (mean 1.19 years) after resection. Excluding early recurrences, which are less likely to benefit from antiviral therapy, might have amplified the overall survival benefit from nucleoside therapy. &nbsp;",
"   </p>",
"   <p>",
"    A benefit of nucleoside analogs has been reported in a few small studies. Given the potential for benefit and low risk of side effects, this approach merits further studies and consideration particularly in patients with high viral load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82761906\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of any form of postoperative therapy following potentially curative resection of HCC remains unclear, and no therapy should be considered standard of care [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Many of the adjuvant trials in HCC suffer from the same deficiencies as those evaluating the neoadjuvant approach (namely, small numbers, heterogeneous patient populations, nonstandardized endpoints), thereby limiting the conclusions that can be drawn [",
"    <a class=\"abstract\" href=\"UTD.htm?21/29/21978/abstract/94\">",
"     94",
"    </a>",
"    ]. Although early data using 131I- lipiodol or polyprenoic acid are promising, these agents are not commercially available in the United States. The benefits of interferon and nucleoside analogs await confirmation in large controlled trials with adequate follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969404108\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo a complete resection are at risk for disease recurrence and second primary HCCs. There is no evidence to guide the optimal posttreatment surveillance strategy in patients undergoing locoregional therapy for HCC.",
"   </p>",
"   <p>",
"    We suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging (CT or MRI) every four months for two years, then every six months",
"     </li>",
"     <li>",
"      Assay of serum alfa-fetoprotein (AFP), if initially elevated, every four months for two years then every six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are consistent with consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is also important that patients with more advanced liver disease have proper monitoring for esophageal varices and assessment and treatment of their underlying liver disease, which may have a major impact on longer term survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H457344296#H457344296\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Importance of comprehensive multidisciplinary care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969404122\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. (See",
"      <a class=\"local\" href=\"#H969399451\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A majority of patients with HCC have underlying liver disease, and need comprehensive multidisciplinary care for proper monitoring and assessment of their disease. (See",
"      <a class=\"local\" href=\"#H969400077\">",
"       'Importance of comprehensive multidisciplinary care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Curative partial hepatectomy is the optimal treatment for HCC in patients who have adequate liver reserve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The preoperative evaluation for resection of HCC should focus on two main issues: the likelihood of disease being confined to the liver, and whether the anatomical constraints of the intrahepatic tumor and the underlying liver function will permit resection. (See",
"      <a class=\"local\" href=\"#H969400084\">",
"       'Preoperative evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H4#H4\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Preoperative assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is wide variability in outcomes after partial hepatectomy for HCC, mostly attributed to patient selection. The best outcomes (five-year survival rates up to 78 percent) after resection are reported in carefully selected patients who have solitary lesions without intrahepatic metastasis or vascular invasion, tumor diameter &le;5 cm, and a negative surgical margin of &gt;1 cm. (See",
"      <a class=\"local\" href=\"#H969401849\">",
"       'Long-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high rates of local recurrence after hepatic resection, several types of locoregional neoadjuvant therapy have been evaluated, including transarterial chemoembolization [TACE], hepatic arterial infusion of radiolabeled lipiodol, and regional irradiation with or without chemotherapy or TACE. Given the lack of survival benefit in most studies, we suggest not pursuing neoadjuvant therapy prior to hepatic resection, unless in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H969401877\">",
"       'Neoadjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A conclusive role for adjuvant systemic or intraarterial anticancer treatment has not yet been established, and we suggest not pursuing adjuvant therapy after complete resection of HCC unless in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H969401884\">",
"       'Postoperative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The available data are insufficient to answer the question of whether any form of antiviral therapy (interferon,",
"      <span class=\"nowrap\">",
"       nucleoside/tide",
"      </span>",
"      analog therapy) after a potentially curative resection of HBV-related HCC will prevent disease recurrence. Most institutions routinely follow HBV titers and treat with antivirals to reduce viral loads. &nbsp; (See",
"      <a class=\"local\" href=\"#H82761906\">",
"       'Summary'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      There is no evidence to guide the optimal posttreatment surveillance strategy in patients undergoing locoregional therapy for HCC. We agree with the consensus-based guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      , which suggest the following after ablation or resection of HCC (see",
"      <a class=\"local\" href=\"#H969404108\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Imaging every three to six months for two years, then every 6 to 12 months",
"     </li>",
"     <li>",
"      Assay of serum alfa-fetoprotein (AFP), if initially elevated, every three months for two years then every 6 to 12 months",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/1\">",
"      Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/2\">",
"      Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990; 211:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/3\">",
"      Paquet KJ, Koussouris P, Mercado MA, et al. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991; 78:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/4\">",
"      Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/5\">",
"      Chen MF, Jeng LB. Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/6\">",
"      Ozawa K, Takayasu T, Kumada K, et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 1991; 161:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/7\">",
"      Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/8\">",
"      Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/9\">",
"      Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/10\">",
"      Llovet JM, Br&uacute; C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/11\">",
"      Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/12\">",
"      Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/13\">",
"      Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995; 22:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/14\">",
"      Nonami T, Harada A, Kurokawa T, et al. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997; 173:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/15\">",
"      Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19:3037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/16\">",
"      Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/17\">",
"      Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/18\">",
"      Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/19\">",
"      Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/20\">",
"      Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/21\">",
"      Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/22\">",
"      Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in diameter of &gt; or = 10 cm. Hepatogastroenterology 2002; 49:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/23\">",
"      Nagao T, Inoue S, Goto S, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg 1987; 205:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/24\">",
"      Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/25\">",
"      Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol 2011; 9:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/26\">",
"      Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010; 116:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/27\">",
"      Parker GA, Lawrence W Jr, Horsley JS 3rd, et al. Intraoperative ultrasound of the liver affects operative decision making. Ann Surg 1989; 209:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/28\">",
"      Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/29\">",
"      Hsu HC, Sheu JC, Lin YH, et al. Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC. Cancer 1985; 56:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/30\">",
"      Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/31\">",
"      Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/32\">",
"      Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/33\">",
"      Shrager B, Jibara GA, Tabrizian P, et al. Resection of large hepatocellular carcinoma (&ge;10 cm): a unique western perspective. J Surg Oncol 2013; 107:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/34\">",
"      Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/35\">",
"      Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000; 231:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/36\">",
"      Kang SH, Kim do Y, Jeon SM, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol 2012; 24:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/37\">",
"      Nanashima A, Taura N, Abo T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci 2011; 56:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/38\">",
"      Iwadou S, Nouso K, Kuwaki K, et al. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int 2010; 30:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/39\">",
"      Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/40\">",
"      Zhou YM, Yang JM, Li B, et al. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int 2010; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/41\">",
"      Zhou L, Rui JA, Wang SB, et al. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol 2011; 37:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/42\">",
"      Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989; 106:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/43\">",
"      Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993; 113:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/44\">",
"      Choi TK, Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 1990; 37:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/45\">",
"      Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003; 238:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/46\">",
"      Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 2007; 141:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/47\">",
"      Wu CC, Cheng SB, Yeh DC, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg 2009; 96:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/48\">",
"      Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007; 141:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/49\">",
"      Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/50\">",
"      Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998; 15:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/51\">",
"      Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/52\">",
"      Adachi E, Matsumata T, Nishizaki T, et al. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72:3593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/53\">",
"      Lee KT, Lu YW, Wang SN, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/54\">",
"      Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/55\">",
"      Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/56\">",
"      Sasaki A, Iwashita Y, Shibata K, et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/57\">",
"      Brans B, De Winter F, Defreyne L, et al. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/58\">",
"      Sitzmann JV. Conversion of unresectable to resectable liver cancer: an approach and follow-up study. World J Surg 1995; 19:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/59\">",
"      Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients. World J Surg 1995; 19:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/60\">",
"      Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/61\">",
"      Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/62\">",
"      Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93:1091.",
"     </a>",
"    </li>",
"    <li>",
"     Imamura H, Seyama Y, Makuuchi M, Kokudo Norihiro. Sequential TACE and PVE for hepatocellular carcinoma. In: Venous Embolization of the Liver, Madoof DC et al.  (Ed), Spring-Verlag, London 2011. p.249.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/64\">",
"      Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/65\">",
"      Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/66\">",
"      Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/67\">",
"      Okita K, Matsui O, Kumada H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial (Abstract #4024). J Clin Oncol 2010; 28:306s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/68\">",
"      Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/69\">",
"      Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/70\">",
"      Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/71\">",
"      Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/72\">",
"      Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/73\">",
"      Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/74\">",
"      Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/75\">",
"      Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/76\">",
"      Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/77\">",
"      Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One 2012; 7:e42879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/78\">",
"      Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004; 10:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/79\">",
"      Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 2010; 17:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/80\">",
"      Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/81\">",
"      Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/82\">",
"      Ono T, Yamanoi A, Nazmy El Assal O, et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/83\">",
"      Okayasu I, Hatakeyama S, Yoshida T, et al. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery. Am J Clin Pathol 1988; 90:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/84\">",
"      Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353:797.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00116454 (Accessed on May 17, 2012).",
"    </li>",
"    <li>",
"     Clinical trial information available at: www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=598736&amp;version=patient&amp;protocolsearchid=5281938 (Accessed on October 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/87\">",
"      Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/88\">",
"      Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/89\">",
"      Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/90\">",
"      Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/91\">",
"      Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus&ndash;related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/92\">",
"      Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/93\">",
"      Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; :CD001199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/29/21978/abstract/94\">",
"      Chan ES, Chow PK, Tai B, et al. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000; :CD001199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17215 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21978=[""].join("\n");
var outline_f21_29_21978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H969404122\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969399451\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969400077\">",
"      IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969400084\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969401849\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401856\">",
"      Tumor-related prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401863\">",
"      Underlying liver dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401870\">",
"      Patterns of relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969401877\">",
"      NEOADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969401884\">",
"      POSTOPERATIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401891\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3734180\">",
"      Radiolabeled lipiodol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3734030\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401907\">",
"      Acyclic retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969401914\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82761805\">",
"      - Interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82761845\">",
"      - Nucleoside/nucleotide analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82761906\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969404108\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969404122\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/17215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17215|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/36/11855\" title=\"algorithm 1\">",
"      Barcelona Rx algorithm HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17215|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/45/1757\" title=\"table 2\">",
"      TNM staging HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/51/7996\" title=\"table 3\">",
"      CLIP score for HCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_29_21979="BP guidelines for commercial driver cert";
var content_f21_29_21979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood pressure parameters for commercial driver's certification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td colspan=\"4\">",
"       Numerical readings must be recorded. Medical Examiner should take at least two readings to confirm BP.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Reading",
"      </td>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Expiration date",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recertification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       140-159/90-99",
"      </td>",
"      <td>",
"       Stage 1",
"      </td>",
"      <td>",
"       1 year",
"      </td>",
"      <td>",
"       <p>",
"        1 year if &le;140/90.",
"       </p>",
"       <p>",
"        One-time certificate for 3 months if 141-159/91-99.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       160-179/100-109",
"      </td>",
"      <td>",
"       Stage 2",
"      </td>",
"      <td>",
"       One-time certificate for 3 months.",
"      </td>",
"      <td>",
"       1 year from date of exam if &le;140/90",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;180/110",
"      </td>",
"      <td>",
"       Stage 3",
"      </td>",
"      <td>",
"       6 months from date of exam if &le;140/90",
"      </td>",
"      <td>",
"       6 months if &le;140/90",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood pressure. Record with either spring or mercury column type of sphygomomanometer. If the blood pressure is consistently above 160/90 mmHg, further tests may be necessary to determine whether the driver is qualified to operate a commercial motor vehicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Medical Examination Report for Commercial Driver Fitness Determination. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21979=[""].join("\n");
var outline_f21_29_21979=null;
var title_f21_29_21980="HRCT patterns in ILD I";
var content_f21_29_21980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HRCT patterns in interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Airspace opacities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Haze or ground glass attenuation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Desquamative interstitial pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Respiratory bronchiolitis-associated interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Drug toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pulmonary hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Lung consolidation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chronic or acute eosinophilic pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cryptogenic organizing pneumonia (bronchiolitis obliterans with organizing pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Aspiration (lipoid pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alveolar carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alveolar proteinosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Reticular opacities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic pulmonary fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asbestosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Connective tissue disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nodules",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory bronchiolitis-associated interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary langerhans cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Silicosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coal workers' pneumoconiosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metastatic cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Isolated lung cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary langerhans cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphangioleiomyomatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic Pneumocystis carnii (P. jirovecii) pneumonia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21980=[""].join("\n");
var outline_f21_29_21980=null;
var title_f21_29_21981="Treatment streptococcal pharyngitis";
var content_f21_29_21981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of pharyngitis due to group A streptococcus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Adults and adolescents (&gt;27 kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Children (&le;27 kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Oral penicillin V",
"        </strong>",
"        * (phenoxymethyl penicillin)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        500 mg two to three times daily for 10 days",
"       </td>",
"       <td>",
"        250 mg two to three times daily for 10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Intramuscular penicillin, single dose",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Penicillin G benzathine and penicillin G procaine (Bicillin C-R) 2.4 million units",
"        <strong>",
"         or",
"        </strong>",
"        penicillin G benzathine (Bicillin L-A) 1.2 million units",
"       </td>",
"       <td>",
"        Penicillin G benzathine and penicillin G procaine (Bicillin C-R 900/300) 1.2 million units. Consists of benzathine penicillin G 900,000 units mixed with procaine penicillin G 300,000 units.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Amoxicillin",
"        </strong>",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        875 mg orally twice daily or 500 mg three times daily for 10 days",
"       </td>",
"       <td>",
"        50 mg/kg per day orally (maximum 1000 mg per day). May be administered once daily or in two or three equally divided doses; duration is 10 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Cephalexin",
"        </strong>",
"        <sup>",
"         &sect;&loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        500 mg orally twice daily for 10 days",
"       </td>",
"       <td>",
"        25-50 mg/kg per day orally in two equally divided doses (maximum 1000 mg per day) for 10 days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"2\">",
"        <strong>",
"         For patients with potential severe hypersensitivity to beta-lactam antibiotics",
"        </strong>",
"        (eg, penicillin, cephalosporins)",
"        <strong>",
"         :",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Azithromycin",
"        </strong>",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        500 mg orally on day one followed by 250 mg daily on days two through five",
"       </td>",
"       <td>",
"        12 mg/kg orally once daily for five days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Clarithromycin",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        250 mg orally twice daily for 10 days",
"       </td>",
"       <td>",
"        7.5 mg/kg/dose twice daily for 10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Clindamycin",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         28 to 70 kg: 20 mg/kg/day orally in three equally divided doses for 10 days",
"        </p>",
"        &gt;70 kg: 450 to 600 mg orally three times daily for 10 days",
"       </td>",
"       <td>",
"        20 mg/kg per day orally in three equally divided doses for 10 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Oral penicillin V is the drug of choice for GAS pharyngitis.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Penicillin G benzathine and penicillin G procaine (Bicillin C-R 900/300) requires further study before routine use in adults or large adolescents is acceptable. Bicillin L-A (benzathine penicillin G 600,000 units IM) is an acceptable alternative regimen for patients &lt;27 kg.",
"      <br>",
"       &Delta; Although single dose amoxicillin is recommended by the 2009 AHA guidelines, its superiority over the doses listed has not been proven definitively, and it is not approved for children younger than 12.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Dose alteration needed for severe renal insufficiency.",
"        <br>",
"         &sect; Other cephalosporins also acceptable (cefadroxil, cefprozil, cefaclor, cefuroxime, loracarbef, cefdinir, cefpodoxime, cefixime, and ceftibuten). Cefpodoxime and cefdinir are US FDA approved for five days of therapy; all other cephalosporins require 10 days of therapy.",
"         <br>",
"          &yen; Erythromycin or clarithromycin also acceptable (10 days of therapy).",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009; 119(11):1541-51. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     <br>",
"      Additional data from: American Academy of Pediatrics. Group A Streptococcal infections. In: Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2006. p.610.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21981=[""].join("\n");
var outline_f21_29_21981=null;
var title_f21_29_21982="ACC AHA Rx systolic HF";
var content_f21_29_21982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81590%7ECARD%2F70468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81590%7ECARD%2F70468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of adults with current or prior symptoms of heart failure (HF) and a reduced left ventricular ejection fraction (LVEF) (HF stage C)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Diuretics and salt restriction for fluid retention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin converting enzyme (ACE) inhibitors in all patients, unless contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Beta blockers in all stable patients, unless contraindicated. One of the three beta blockers proven to reduce mortality should be used (bisoprolol, carvedilol, and sustained release metoprolol succinate).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin II receptor blockers (ARBs) in patients who do not tolerate ACE inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Drugs that can adversely affect the patient's clinical status should be avoided or withdrawn, if possible. These include nonsteroidal antiinflammatory drugs, most antiarrhythmic drugs, and most calcium channel blockers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Exercise training as an adjunctive approach to improve clinical status in ambulatory patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An implantable cardioverter-defibrillator (ICD) for secondary prevention to prolong survival in patients with a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An ICD for primary prevention to reduce total mortality by preventing sudden cardiac death (SCD) in patients with non-ischemic or ischemic heart disease who meet the following criteria: at least 40 days post-myocardial infarction, an LVEF &le;35 percent, New York Heart Association functional class II or III symptoms despite optimal chronic medical therapy, and a reasonable expectation of survival with a good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Cardiac resynchronization therapy (CRT), with or without an ICD, unless contraindicated, in patients who meet the following criteria: cardiac dyssynchrony as defined by a QRS duration &gt;120 msec, LVEF &le;35 percent, sinus rhythm, and New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Creatinine should be &le;2.5 mg per dL in men or &le;2.0 mg per dL in women and potassium should be &lt;5.0 mEq per liter. Under circumstances in which monitoring for hyperkalemia and renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone antagonists.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and nitrates is recommended to improve outcomes for patients self-described as African-Americans, with moderate-severe symptoms on optimal therapy with ACE inhibitors, beta blockers, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence and/or opinion is in favor of the following approaches being effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; ARBs as an alternative to ACE inhibitors as first-line therapy in patients with mild to moderate HF, particularly those already taking an ARB for other indications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Digitalis in patients with current or prior symptoms of HF to reduce hospitalization for HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The addition of the combination of hydralazine and a nitrate in patients with persistent symptoms who are already taking an ACE inhibitor and beta blocker.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT with or without an ICD is reasonable in patients with an LVEF of &le;35 percent, a QRS &ge;0.12 seconds, and atrial fibrillation who have New York Heart Association functional class III or ambulatory class IV symptoms symptoms despite optimal chronic medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT is reasonable in patients with an LVEF of &le;35 percent who have New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy and who have frequent dependence of ventricular pacing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence and/or opinion is less well established for the following approaches in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and a nitrate in patients who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an ARB in patients with persistent symptoms who are already being treated with an ACE inhibitor, beta blocker, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not effective and may be harmful in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine use of triple therapy with an ACE inhibitor, an ARB, and an aldosterone receptor antagonist is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine administration of calcium channel blockers is not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Long-term infusion of a positive inotropic drug may be harmful and is not recommended, except as palliation for end-stage disease that cannot be stabilized with standard medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Nutritional supplements are not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Hormonal therapies may be harmful and are not recommended unless given to replete hormone deficiencies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Management of patients with heart failure (HF) and preserved systolic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of hypertension, both systolic and diastolic, according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of ventricular rate in atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of pulmonary congestion and peripheral edema with diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Coronary revascularization for symptomatic or asymptomatic myocardial ischemia that is thought to have an adverse effect of cardiac function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approaches in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Restoration of sinus rhythm to improve diagnosis in patients with atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Among patients controlled hypertension, use of beta blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers in an attempt to reduce symptoms of HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Digitalis to reduce symptoms of HF.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21982=[""].join("\n");
var outline_f21_29_21982=null;
var title_f21_29_21983="Primary pain pathways";
var content_f21_29_21983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Central perception of pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 474px; background-image: url(data:image/gif;base64,R0lGODlh5QHaAcQAAP///0BAQMDAwICAgAAAAPDw8NDQ0KCgoDAwMODg4HBwcFBQUGBgYCAgIJCQkLCwsBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADlAdoBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhDEKAYiJiouMjY6PkJGSk5SVlpeSCoWbnCwBDgKhoqOkpaanqKmqq6ytrq+wqQ4BnbW2IwECt1gCtLu/hLnAVb3Dxn/Cx1HFys14ySOzAQoJPAnVANAnBQYioUUJByfX3ro/3DHMzutz2gMMBQUHDjwDAyLaJszfROEn9uWAqHMxkJ3BNtoCPChhIFG3A4caQAzQoAAAAwgQWVSAoMG9Bg0CNGRA0RxHBOIY/0AIcKDlxYwIsImAqakAogYLOXq86BCAzQAIHhjQdABmN5AiXT5AgAAeAAURzY0oimABgKVNNx5YcEAly58IDBRY0M3AAovefB1cu0bbAwgMHHQDsECXAKvvfBKopoBeRQBdBSAQ0Q1gNnEPrDq4B6BBAmYAIXQrINPnTAMDNF0UTJiuXasL6G2mhTYxAMMA/w6gx/Kq1REG/h61uDpbrse+6gJI0ACAAMcNpPpWy7a4mXzhFEgEQGBEc8PNTw8QsBJogAINFgyoZlhYMesBIITyZa/giAGIxP+OGy/7dubO4Y8oZta6dBHlfX23S9zw8LTZmMMMAYlE5wAE4pBgnv9xDH6RzwgP0AIBWhDcJ195g5UggHIWekeLQgqSN12GJTjwmjAFJMaANxxOKEKFBKD1n2T/oTYARt5Y5SEJmcGW4V0BAsicjCI40IBo8xHX4JJdaKPAQgUwcI+Up60IHX73IEBPOAaIY0CFDqxoE39XxXSVAbH5lNpCAswFgIm+BfeALiZ2eVGFVObFgCYJzCmhWIe8KWZqAowlzo4jJABBNX4VylWQF/VWgALwFECPYLwJtyCTnFqhjQAktaZmAANY5FI2Irg0aQALPLAqWT6RlIACZWmW2DS0KeRSAiQpQOQhmaFJUqWHwFoAeqWOygCamjTEVU2y7kpSgrRepNn/fAt8stu0IlSLH4jSODBWWWcl2em5WTyIbg6bruvuEuq+W0O78tZLRLz2pqNkvvwKgW+/LdAL8MA3/IsCpUOQ45twPAhswwGVpbCnDA4TbHEMBpuQwL4+GMaPDxXTALELAUTMQsgXp7xCxiUwYA5ECyz3FFNeKoAeYExZhZFGTykQ81EhdYkYU05BVVIJNOETkUUb20eC0cEtUFW3NL8ElJcMSP1atdNQZJFgiCQIqr4ql10DyySQmFcBEy4mgmPUgRKbRbMBtmJrnNnYGG2sIfbaCGiFxRxf9LT6HwmtLWVRWG43lgBabPuGwOLdCLPXU/S46B+JBHFs9ucqoI3L/3mM5QKeeiLOV11GkD7HWH4AInpeerpEB1B0BSFqekbhFRpqc8wIYzmWkDGGKgwog/656PiQfhmI5p52LWeI6xK5jTj6piOZ0ZxYO5by5c696QuNEJoIwPsi/PfSFT868p4rLz8uDHty3oq/lVmNUMwoyigAWtrNocSRlzCp6SOOOhT3imSV37APIOe7WfUOl4ul7M8s9DhA+vChi+HdRzJjMV78UJC8+aWMeadJEHoCwABs3MpXQ8GWtl61EFaRyiJRKpm0RFWtGD6NVFxLlTii9KwS9FAz1XphPLIVIWt1qxtBBIyXFsAAKgHGeJ0zoRZLgMICTM5COEBhGQo1Jv+ffBF+W0wjpGAAESnqwFt0kEb5FJAgNKpRi2K0WAnvyK88EmyPfLSXHwcGyEDKi4X2SKQiF8nIRjrykZCMpCQnSclKWvKSkSSJIeV3AEx68pOgDKUoQ9kAKV2yjptMZacGqcpWLomVrozlFlCpBVjK8pZW6E2T6ofLXopBAARwUy156ctidmEABMBiuohpzGZiIQAE2qUzp7mFAhDgmtKkpjat8IBrEqB8w9ymOKegAG9ea5njTOcTEOBNzj2TmeqMZxAS4M1rmqwKtpSnPl2gwXrS0lPw3KdAcfAYYIbinlTI50AXioLocEGhDI1ofLIp0YrewKFbgKhFF4rRKzT/JDwZUeZGR8qCjlrBmv4kqUpbYFIrsNObCF2pTOWjhXJeU5czzSkJWkoMb65Ip0ClqRa8Cc6gzpSnVVjANYlk1JUilQoOIIA7m6rSp07BAMmkak6tOgXxaPWoXvjpV53qBaaOdaNcPatai5DWtZptlHCNq1yTKde62vWSbuUCXe/K17769a+AZWRb89qEwcbTsIRVAmLTudjEHqGx4oSsY4kgWRYkIJEmE2kWxMJBFSjsYzZQGBMqO9kgkFYFghHAAxogzNM4yBz/8lhAXeCfJZy2tD64LQlFNJSb0cIAWWvKAY5WFKA8JEyUmosChKOTe3xUJICJyERkw7uNdORG/xBgHQuPBhagJcVLMKkMVayClaJt5QBIEQsiwjKui5TrB7rF7Q7iqw/1HSBu3xPM4vxmGdecBicGMKCiFJShbugGSGu7XF/2ZjfqVQ62/NUNbywUmcnIZG4XYXBtECGAyzJGwr35TaZMK18q0FdDK0GAJtSxwSDRJ1usMwx2joVF7GinGg51HfqIt7rruKcaydgRgRCh4/ZxzD/7+JA5oFOgIiFICCcusQ2iHD0hwSd4ZKJRMfwTF8foo0UUspDtRvTl3gSZTDHi0evIbIIeEeZH2wPfkEp0JChLWQpUtvLhrqy+LAOKFv6hp1gJ4yU83SMvV7pPALlUaLocwCI7ov9UPOhhQBo3hk1u8t+bGpNASFVa0paS3IiBkOc7x6DUPiTMtX6LxFrxpIineltrXzUZZJkqQb5QVbFcVSxyWeWIRUIEPXIYDnHwClcKytaWuPWUuRD7TcJur1nMqoNSm5o6XImpUL9QSGVY+87A9GYpXWWCbwNhOu4ytyE9HNi4MqCe9UQAundMUnUHkp7tdje82znvbVfU3oEEOA7CfdMnmdWkCDOXP14wshSANgXoWNi8RoiCiC8cvhripWhjcI+Im2BiJRD4HUVuA+owoOENLcHGNESLi7cA5Sd4+G4DQoM99u+f8834PzTbgnu0q2QhHynJKdsyczSNdTGkii//TnIjm9GCa4dAQC/q7BKo6WJnKAGAV1oytKxElyKiaWOIeIII5TLlRjBJyUoOEMPnPiQiSEqVUb5eZ61npKNVj0pjgtZdutNjZ16mxdaX1S27DNrfDB36EDpKIsMVoxhp7gacNgMBUARJwWKqEEASZxXIVch9qqHH2ioUXZZ7Rntveg1nffJ5/dDiwHjJfAlKE3vWv0kzHd08fw0D4irZHkSU4XORVjTgmQQdrW7oqFpwR4tiSA3d0FCHB6+0eTLlEJqHg12NGINUyMcHGtdvsfd3nGjYwBjQ3G9dCaq/ffQ1+UpGouOOmTFj/yhJ8VrEP4kRN9HH+yLAiwI9ezZ9/+nHfs4nGi1mD9mDYOk3cy4CABUigOcjfDMSZuX3It2wZemXDLl3DzsCHUSSaOGQdS2mdUYiE/cndMnHReYjes0HaO3RJdchD9L3QAXogWRyPhoUKQfEaYYiZqlyTv+RJysyXPGwFRnUHGlSAMVAhEBIAiAUKPDXQB3oYrTwaZUieunnANVwPkooKbtBAIOWgsjXBrmXIETURjEkR6nCKkJxLVF0KrRQda42FgpBHrpibMwmh0HIEDVha23YKnbYRKehEDF0LDfkRscDG6zSRnxYiIQ4FeIAbM8WLopIC7dSOt9SPqw1Fcqkf/MDihhHAl5Ebb6kDqV4fBYlirllAv9iN039Jn+q+G8rWG8qaIZVdYtswIryw4uf44vzFQvCOIzEWIzGeIzImIykAIxlw4w5gAnQGI3SOI3UKI1DVo3Y+Ai6uFbOuFWE1Y1glVfgKFPjuEnlmIviaGo9cI4Bp448wI58BI9l6FbyuIrf6I45l474mAP1mEb9KFH/mH/7yI/3OJAXVZAGWQMBaUILyVEImZAz0JC9CJEKuVaYgUz2gHMUqQISaTZYVU9xt5El5VYNUE+tJZIc6Vbvdk2kh5Is5Vb9RAB/45Ir0JFmQ0/XpJE0OYtn9VLatpP0tlblhFNAmQI2aTbddHhFWW55ZU1FtZRMmVfXAZVGSVgnSZX/E4WVJXaUWjkIBqCMYCkKBBCWYXmVVECWaJmWaalN4JGNbvmWcJkIrDNUcVmXdhmXXPkLGnUH3WYEeRkFf3kLe2kHfclWxRGYtjCYdVCYRMcWiFkLikkHjLl4OeBxF2GKqqYhS2An1caWs8UJk2lnA0cccBRzSkJxL9BWUeIAUPGZI0lNkTkHobl/NzAQIzMAEeIrJGEX8iYqjBEhhsMjLPQQLFQN4SAA05FMUwQiD1A+zbkbJemarzlN0UcKi4gCseYDr/gDq6cC7TV2Q8UuxGE54rAAC5AAaSJi2NENzaE4LocwBvAAW8GEIQYBNzaWBpAAMTEm2BEKFbGarUmQ/7ApFfaACLezArXFA6nYA8lQminQEKYXnqM5QWM2f6nTHMFZAg94etnwlcsXbAXqXA0gOISWj9TJMP7xTSyUIyxEG/cwXKSSKolxFuixJQkyMhEigPiRIPXxm6zSDeFQo98CKzB6D7xBJSNzF7pxGhEiVi4DnllwWwNBgBYKPs2hLhh1ZiyGHy5zUDOBmhU5oOtnPARQnl7CKFbicxbxKLjiAFKHHbjBQXPjcgA0AiBED4lBGRXhQHAKJ/HpG2v6aFrSQR3mGLyBY2bKIlCKBVI6njZYpQDEnr6XYbjAo6zpEyG2fF/zFxkGFVBBap45phMFEJYiNei3G+ixE7ozHv8cpCiWx4Jvs1xrakrBgWVFwXYicFkUgYMc1Di1UaHNU2WMyi7VIRJUemUpln5RElIk8FyuwgBMwSZqMQAqhjNAIZ+D4UU6OWWhqmajmiXiooG8sRAG2GdYhqpz+T4+YSIT8gmiwIR95hvKsR04cR9npjfAep2zGQMYZJZZeRCP2Qn5kKJWairoRz1Usqo44kUdVg3WBKu+MRPI+RqUgWWcFSEI64HlkwvZA13AyiuLigQEBxcw968GEbCcMLBkCj7otV33Aa2swqvnqjVSp59XU3QiIDXVOjNAEacBshTGZXcxWyZKdhpnR2+ogUqppZaysG9SZXAmyw4ouwmxeQP/KxcFXoRidxkJL+W0E4h4zjC1hVC1N5BwTuBFT7mvyANvKlY/HTVtOrBxDLetN9CdNPCdUVtMZAsHavsCwDRumKl8/kpbjJGdL5CgPOCgMwChO9Wtx9C3LhB80+kbYgWcQNpJLGEW5zkqyWKgBbUtonIAM1oNd9GiYCQClvsmcyEXQSoq9VE+27EdI/O6AiSksYJs6OEUWiccYhsM0kkIkPuOT2MOecob9FkoHmEpK+KEVVQohPKDbboi+Skop1u8FfElx9JArLWe+vk4lkMqG9Nh+5kLfOplWfeG90CIG9K4YqoMwWuii0hF9lCr8VoMLal5a8a4QLIjpRpjWCS//wMQHDjzRcUzCyFKU7lgwMhisZwDAYnkUMTRu4Owt2/wvp2pru4aCvDaWeMHHzaSZFYIQOF6qrgAChqsF4xRPO8gCjhGPyt8UFg2EGMpCuoKtr1EwW5gwQIqAi2EHxTrszvieHihGZHBNyGcZsN1ugPwwwC0FNJ6Gb+BFpLKQVFMGFjGNg67MaIxFyCbt76Ew22gwziAUZ00AhzRs+dKHz1hsxdZJl63Iy2rSQl6xjExMbHxlckqd9eKwLpQXEFxrkBbMmORMzvKvifaDGJ8kGmDmVmQyKToThIsCAYjD6vxkzWQaieTuFcZUI4cphByRtwGpjuAtjxpTAYjbwJgJP8N43o1WcNhxEsU18k0EMl+6bimCTht2MNMiiu7ibo/6l4xGsDT0Qu2S7vANAAE5MsZ6hsP0Mv8wBj1wRpXx0T4sQKyHJGHacsmwDaymipnkT/MUZ7nmSbWyzZikUE1W77XML4dhp/w4Z6ohB7o2RtXwhvnHCDdW0ZWdc0yQMuG2b4poKtwwaEeK2cYSqu/0c0gHCAKHKM5RhdPadBAeKn009D3sM+iXFhMu9EcHQv+jAzSGRxndiEbaMJkxK4bTEHI2aUdRlNXykvUd4PV88ItjdEZtbVueY04XY3azBDm0Kc1oUvA+hw/bA5SRz0xzKnsiRbP8VPCBH98Ajy69GD/VZxhNg2wKPkvCRAze7ysQYG0DUjHW80UmhE25+rH5FqtzbGsMeo88IEd02A7GRFnaG3DerYOH21CYMwG/PwGeT0/e70GfV2LGxnYajDYuCiShp0GiL2LWf27g9DYa/DX8rPYaCDZakDZymPZZ4DZaaDZoMPZZuDZaADay2PSHZ3aHT0La2HaZnMIOx3bsr0IQhi2XbmVty1fru1MjPwEvc0vu91MM3mWIXkxwW1MwXQFS/yLuQ0D3VTcUYAALWkxBTXDltzc5ZTRR4BSkN0pMXlN0N3cSINNVdBNWXUxKOVNgyveODmWVbCS2o0uXTvd4n0CMVnbT1CSS5UyNiWT//WtAispVVTQ3t+UMgRHt+Kt3/stBd+N3/0CU/+NAh/pTQh+BEolbioDTUQZ4SSQo9klKlEAY9WhMlGllBw+QVZA2oSAVRF94vRzBSpOCBvq4lzU3UUQ44PAczQu2g4X3zQ+MDw+cz++RUF+y2SAnPmW5Eq+5Ipk47hU5PVVBsjC5FRe5XzV1voE5RE6Bog7P10+TloesmDw5cpD5tsU5sIaBmb+OWsO0Gfp41PQ5l/Z0itgtziAyTOguDnQRkwIWtMLOJ3Ehe71K4QrUGh+12Ou47ggJVmnAno+cS0QL4OZir+RGWe0ErAhEQIwXHRSuOjxAA7urft06HsGA/0G5/850OYoooTUfBqXFQ58gQjlo6TvkcJLZrqImC0S51rAzIWl9KIG2lmAgx7yd5zbQRKwIuiA8dRis3QvygBe1hjCFDhogUxg2uaHnOI+DiomvBRMoOq64D/szBzgKwxQYqiOwbAk/RTp+3TADoT2bCleZHmF4mhrxO6A0Xz2uR1l0Rs2w3pEQiLMEBcQvWDZ02YLgbmgzgLY7kykvkcUwTs6igSqLiUSYdF8LK+9Q9FU6sD20BwuooE7RtHCrquqKhwh/4JTQRLNMWFdAbGVDq3xUCE4wgywPRfIacaFPuqQXUcpIhBw/jhQoOqgQBss3cIctBQP1h2POsPfwHxAWFv/wjCu9sq7AGLzPRwdXEGi6ppac3EA1bEXxSfsOc9xit7TK8N/PwBIDrDFw30E4D4fSs3HPcKwhCh1EGgRCbvFAKQLTXSp9BQnnQEiGXvveN9EwbMQgR8n+6IWAxGcC1ZFL66Ipn72bl7n4ZEIO7H2cD6e32752lDXEFwoc433HAHtdBIS2uETOqszVaFJcF1O+DHXRCu0q68NGGGeKh8pcT0C9YqzexY5bzYqiKDLQGf2hi6dTMjS611ycL65xrcEDa8DPI4WL78CE6YxqD4fJs7wlp/tLyAUqNv8NQfnsWEzm68E0/+MTr4DLTuVK3ByB9P9LRAb191m3+/wkK0W/10MAoA4kqV5ikKAsmPiDEI70/Qw1Lm+873/A1G3ILFoPCKTvIBstxo9lQDVLyG4NqU2nLbr/UqH4DG5bDYxlwdAQcGVUnuPBiSAQJxJ4tFBwVMY5BUB9hgU5Cms6b0JNjo+6qTtFCwQEDAcasUtFaxQOu6xIWRGZkE6meYQHkm2FIwunsrOyrYiWQmQ9mw6ARBG5YUOKAIMBGBOPTBICiwsNMgkLCtKB8SIGCMLKEseHCdMNXEZLwS6LJcDJBwYO4h4W4ukNS8MgBcsjwekH4AbLARwR+LBvgcA/gUwWIwgA3UNGODAFw/AAQMOZLCLRWsjxzK2aiAMEMAPiQMI6v8NAJgqBy8dCh4IQKAAT6NQNH3hIFgsQAIDDdQhSPBKBjRKaxDIgIgTgE5jPX8eWFBAwE8xBAA4WHBQoYieB39SzdUAXC4AC9YwSRB0KACkOLNuBZC2gSGBIh6MWqdWaBoCa86+uthWhhu5Da611dhxMeMkH2kgwCsgEQkEA3QlWEByR0seDy6DYhQFwo0BV61iJcnEwJNmBmgOIX3jNJerC5oEMIDaZEUTB5ZdjZMmgbHDcgU4UC3A541pCHofT35iAVcH1ozhuFoMRxrmA5YdJwEsVOPy5pesnLHCk1Y+KIjp6FyDfE3RIwhgkYFaDJM4KuIMgR8W24lwlSRMoDb/hQLGjaAAA+AE98RcBg2BIBf9IXVFIJMZZ+EJrXyHBYTYcCdDTFgEYst4jJzXoosoPDYDHuWw1oV8NAjQEAuTicQAfEmEEkVAIgSCmk6DAQDBIQM4UICSSw15EIEAXCVdAT9Jl8BVhjAFTELqRCjPFTQpxcSRSDlpjgFc6tTfT1KO8B2RVGUSiHYVGpQmkeFBodiLfwIaYwsHFGAABBCYQ0IzIo30w40zHFAHoySwxkATxEUWBiOWikDJHVolOBMDbuGFADImARTRAp9OeRU+d+TZwEhX4WVHol/NOoWESSGwT4m+mArNQb1aVisCKerXa3udjhqPSXYYdGdOvQ5r/8evKehIIqDb/ikoC/200ABMGjoKjA64DDhCOiW8oikJCZgbRCY+NpbJWI3x5Ce3+zLmLQq3tbBsEI8OmuhmbKCgyxHkOXjEqDKVJ+tzjTFw8JT8YtyRvydEhaIJiXjsA8EsINaub6WxiAR9GbOcw8otw3zGxh8z2mgJCtRscXzx0mCJzwSkzABKLxdBdMxHx5ky0kt7MXMJiRYAjiY84yg1jGQYzTTMWWvddRBOixf2CFewU9qPO2vxAFdehJif22/DHbfcc9Ndt91345233nYr5bXfjqWHAnGHNZdtOGXfcDZLVBNh2s9dwFOz5JNTXrnll2OeOeUEaN6555+L1P+ArKAHoPjfp/cAtjoDEM6kwkiMjDpj2pnHtey3I6F6DiHZvAvjrpiTgNVsGIDuFbgfQXt5tiPf/A+61xAZUpSJ/DsLCjTRCaWJSO48Eco3xrz349cAPQ3rsSEwZ9Zf3Sf53ov/vvxoBA7EjGuyj0LsJzCgkFoco2x+TIufAAUIvQGY4wBre0ehDnWr9fngFb2CwAKL8YzvqK+AGLuBSAiowfFBLwqfmBoQDFAWNMhFHh+sQf1mgYCf3WSFMhQTD26ivae9EALIqB4P1iEAlKUsAAUYgEFiOEMTgK8jCviZzo5YQOg5aBulM4GwhthEFubvXQf4YQBLsMUENMBUTkT/QRI58oCftXCMIEzjCawzRRMILIsm2B8QrKDGE5RxIwV43B0/aL4Z+Ihst3kgFn1QjUmZwI1N6iMJ8riRAFhCjoxEneo4+LN44UxyV2wBHUuwgIukiwQKuM1kMjjJ8FnCLqd83x/H0EkSmFJsIjDiKhljAEsQspbNM58JyUXCQsQglHzgiiR12YhDGZOVbPRkr0SySSK8kg+jE4kJHPczR8pwmadwRjLJBz1a/pIT3ZwBNmnhANON83TQ2+F7RlCACi7OBwhMJwvKOQvh0XOX2hxbM3vnPhXysAcHmGYx72jPfCK0FDwQV8iIFABJBYBBvjOk2xJKJYtiFAjQiyUb/3LU0IlmtGXXHClJS2rSk6I0pSpdKUtX6sd9igBkvoRDQb/CR0UBEZ0hNcJBDfrSP+QskRDwWU115YNyrCABOvvODXBWsZ12oadqlKrsWsmCBrwOpEsAwINSWAIvJYaRMPUCVZ1YVnWOtQAwSBwcjRBNETDAAL+Zgwk4xYafgPOIZ9XCXmXYV6+FcEHtWMQCIMLWgPYQHDgjJBgnSCjDTXUWfw0CPNY1g+NRRKePmKzWQphCaSwip+XyggmzGllZcPYHQ/AJOOxIKXOIAZ9EgpoAhneG1C7tm3IpwA1pugSSnsB4q8RtEYjLA/78cCRBkYty1yC63FSoucMyhmaj+v/THSjgnaI7G+JuMNYUFHUGDiAoVMlanylAAIzv8MM8ViCGCploBct1UiOMG7NWrulDpSnsl3jw1q7kBw2mLW8S7KsD1h3DhK1ZT3ynBF+jcg6ReTBwyyoJxGGgsFNSKeh/51CHO1QzlwQu8Hm78iZlhIcK7/0VFdILCQqzzMKiLQEsDiJEDtf0xunzDXlP+V2+llgeRHRLeymSlgdTwSRq4+gXYJwxq6LgAZJCFHK02otfmMB4P36fk3nQZU6mgh1SA9c63nGZ45FZEbqZpyC+vC/o8e6KmB1tD14Sk5mQoFBaHq5k6elmbn1TMtRLgQC6W139hZcpoBmBAbhXMz7/o9bP141ECkdIaEPTuQfCTeifa9Bp1H26W2O9X428aFvE7mC8j85ygEesBAoXqnmhfhH0CGUoRMFxy4rK8YCx0mNXI4HC/9VBoxczaxdBmWOkXE6md8BmGPUa2EEoY23decKnVbtTUjyBCUuQ7Y6euqOZiDW4uX0rZtfAtYxOVGlLcOwWQU+tZqMZo57JyWJm8tdxEnEfdU3iRtbDxXgZQKZSIisHQCRTMTHGCmICSa5WTIhUCrg/LDPFY5Bm4dSkAnM+KR7pdsJBDSkylZaY3JmAw5kTExqeGznpHDTADYf17Q56WdEGhW7Vk3w3Ht2treX+zxiksIh8N9RwujBF/0cKcIe02nIPCMiFJMcyKhXcgjAoNJh6xyI5AWK13hSvgACHUBjPzeNZV+DsLED477fhY/NW77zPLicQ7WjzDpmARztUANA019D0CFNTEnpveNhh1GA7MIo1Db6oUY1aZAfUgUVlL88Bwz0Cy1yhHs0+cBbiZQCFfB7SpwBf0+91pVYdosWpJ7wIEO5zArkY6yJ40t5XEPuvNljtso+DdtSbdLAzGun3eTk5RxovERb1rRFtJrVK0FWAxj3Scx9CSpqBAzEgwAEPAIgvLAWeOLwiBg5guraUvH0+RZH7KmbCAVRZZJ9sEXvf2f4TaGcNyQA/IXMY3uTx5e8TZFdXQP8W2vjXMAjTP3mVtPFUCXABZv1QE2DWEDmAXL3DBK5BmXUKOxBKMRAakdxAIIBLBeoEBv7QBvJBa1EDDOTJ+FEgB/KBPbwDCh7EDdhW//XLWImQwJBU8iUayQSgNyhg8rTIA2xRf80O8bnCiQiSjdQUPkRSLinAUOVGEC7geRAHYjSGDS6G6rAGRFmWEvyXGAybE/2fEKaTFmrMWPFbEvwXWLHLMkgYI6EhGsIMHT7Sd3GR5blVTYlhvDCAAyDFb4jei0maBh3QdQhLOE0CAzwhCklFAsqhZJHOJFJiJVqiJdohLehWVzCZYKAaEizACzTJm0TfKezNKaJifjCApaT/YivqDRLKiAswmTckIgRpGhxSk7cZwgsdGhW2jAf5ouw5GyIukx7uSE19EtwFI/wozTKeDx7SYJQxiTFeFjI6owDN2TXmAC99FFxZw4JsWYdhzwEmk5ZRozau0kb1k87cBLxsXg5ETi6m0wFckyqh4zhtIgvskKX5Vw/SQLR90B79zBre4ymtU6+tikgggKzY2wlEkw8BUQuwziLd0QtZAtSN0QH04j2u0zqawNvNFAGeyxZFZAtYRDOu0BJZApMJEDAuI5zlByGtwsD4Y0IJgM9s5Pi4ZDAmW13BUz9GUCUQwBdmUvfsnCWco/zspC9aGCQRVSJZxswBZQ94HFPE/xBIZuMdQRIpkmEZKmBPehHK5OSuHZUs0ZMDXEJBIpT5fIYDJOU71kAfYEGGyANwTdIt/aRa1tI6fWMtMhpAOBNc0kA8xuE4PYleplM+uiONCdpYjk1NWhRKfpBGImYLHKSGoRB7COYMhJ4xEBJhVuYvSiZiqqNCMmRlmAX+bGbAPAVesBrZDGBobstSUiFMus2t2JoDrSYLrEAfQOJ0yGbG0GYQtpJXMKE8rYoM0BK60FWMXeJzQmfm8EtWBiefRIIJQYC4zBFg+pMt9sA5xYUX1Uxe/omAuOJ5oqfcZGJ1EoFnuU68MFRIemcPeReo/c16sqdGjdorGEK8sGQ87f8C4UxETFGOSN1nfsJMrQ0lVqjSFQSSfIrkDoTi5VFKM2zRNvxni+Dnq/ELZSKodRYB5TQkoh2V1dASMGToeWzov3HLcH6lGjolO4FhTVEFB6XMDaQeV/IL+Hzbt3HbFa1Asf1AfhFPR82ZuqlbgfCLi0pbCIlDyjyAIQgNQJKoIdWnCeDDUE0dy5BeawDNvZFR4/nAQ5HF0Q3AgoCDaeAG6S3paOrl2UEfhWaF631ifNhD6B1oI3HKKuoDMgzRPjScOCjp3gGENhRa+43ZrVhDQ9ReTF0feEgDm7bAOsSmKXplk+Lgk6JQ//xmhOoAQaRBDJmOY3IE6f1DZgxBYej/RGEAYYKESfFgRUMMAAQkQmE4iS4wAU80qlmswQ2UQ1xJKrs8wIL4zIdSHoxagozKw4IUSqXiCK9dAzCM0vAMUV69CJuKBBclSWlcBe25V20MqidkBbXEFlRAVn9YSsPVQcyRiAoU3tylAMGR1JxNRSjVK73C3b1mgb5am71eKqYqwRDJQJTu5r8QRy4Ykbs2x8RkDJuqWHYE2OC1Sri2RZM8rLqYxAOlQemwXkpoS1+8XjFY5A5GAWtImMnKI8qWrM6pLKOxLGQCbM01QJWokogRpEPW1GscQwMoTr2+pYqGLIFESSCQygpkiXaEidgZ2cVQxfGZiKw0nuaFQrBm/yADzOxNbYSHIug3uWNvAYBftl6KkqUhwcC/mgfVDoGnnMSw8Ndd5cpFJZmsgEcoaCfuyQPriULZwKuSooBFLMBQLQaTAptneQIwVAMoAeKizSdIwM3paKHvARmOBK6bqqWTCtEfZlnZPACV4ixQTY7jygK9WNe+CK6rxZtQjmjBzs+KBtt0mu2IgSXNCVQX+Q3rmqGx8ovqcJFYHmcPGBwGgW7t4i7G6C7KRKHYTuVWSUjweo3tDq9lfle1kiqAcgIRhZXwYi+3aG1+6o70gsF/fVEYOevRAF50mq/5Oi/JUG5Bqg5eTG/yckYgJKnXpGfemGf91k2bGmslGV/v7v/AqDxESKUvLZQu7L7uEUTTP8jDz57SAM8CdQZn7M5oAWLDARvQ82qlBRdBNKkABxkWBoNw7mowNBXTFZZkCKMwrY0wTaaw92wve0owG8IsQq2vUtYwOsYw7MxwPjmwLBQwgeUwAu9wIarRD5dXEO+hXvawpe7vCq/dECdmC8sQEm8wFEvxFWuiE6suFnNxoGhxnXZx17xwdVIxCevlDZOPEUNVGbOwWi4xJKjxTrHxEytxH8VxSM3xFkvbGz8CBMtmHotMhuDvIBMyejLw84Tx/AByIZxvIzuy+UpUIsvxFxPYHUuyAVFyeVnyJI1xBGcyVG0yGuukKDvjImsyKXv/mR2jMk9+8k5tMh+HRhOn8Cv3Wysnpi1n1CZb8SWr8CyvMi9nsC8DMx7jMkZtMiN18h8Xc2T+ssuosiyjMC3f0TEnlCmDcjN72jN/aEAUcjd78zen4iFfjHndkR+HZlE+cjqr8zqTTiS7DDafzzDL83l4EDXP8z1Pru/CMz7z85/U8z7P4/v28wz98xgA9N/Y80CjTkGDASwHmUKPE0M3mTZDdESLsjSrkTlX9CRJdNNs9EdjzUUfNEiTtCB0dEmj9IucdDAmc0o70UqHAUW7tEy/8xg4tEmP9EwjtEjbNE3r9EvzdEPXst9gJTin5/DCtBLs8jb3EzujL1IH9U8b/4E1V6GxJrVUp84y/8BNv89VK2BLJ6hW+wBXp3FUwwEQiXWLJLQgUHVxuQgEa7TfeDURnNHPCPRC5zRH2IKa8q16fNcq6M7j+oVEKk2q3uzSzPX3/Iw4I89a58FegwfjqRVFylsgcEllmxkEEkeeZJ8MGAKsqoP8uk7QgsKqvAdTxasi4GhnzyAWdk1if43P6Gg2pfUX7HWIXNSVaCRWBcb5MUFvawVEqEC0xEBkgFGZIIeO/CFrEKERaeFY3IsnxYCz3IYC+AENPgQOaN+JyLVZSwFaJitE37Y7XoVv+oJGGg77ZQsYXYF1MJ5v40YuKMmV4EMwWV1fO8Jr+II7cP9Rbb3JEMSn3bVCcuX1RsB2CfkMeQLzbXPVTTpYaYiHtqZA6/gdePFJGviIIB5DafDfKeDMd+ABLljBEwRIAD3YK2BP37y2d0vBUCmtQjM4vNBKe/QPECIM+z1B1BzmIWiHdByIZ/dKIKi4LthgfEa3iWlLIi4Ji5F4gRMwiytBJVirBoF1hZmCGDCiPKyihCRceGw4HgzUdzTEJaDcTrBXEzTfKyTcrfSffseUPbJcPPiEdeMB9Y0Eio+Kk8/CgQMBPaZuV+t5LZiCbE3FulUokdTJvqIbASRpfnGJOgxPu+0tEjzABNKAbBXp0wiP1WCWbOXXVGx6d+szGGhJbav/daCfAiAbF4w5zkOEIA1DuRLMNkGjOiQA8r+y+kjJxObSE58DgYIXUFzHmKnrQEsZu0ltqRnc5LEvtRH4OlbzZjG/+g7k+s+4erQN0SEQx0ZauhDTc6xDOyr0uWqjMchSuxaYBgR80s/Sy5XABKSo2ZTD7/deWL1fWAfZe77je77ze7/7+78DfMALvL8T+7Z0b9lCXC7gU/GM3xRcA7lxyTykMhx812KaRG2t2aVE4yqWBYYlcRlgx8CL/MiTfMmb/Mn7+4AqQZUP+w5kn29bwxXKBXUIDRFhlXDIgLkXu4ErBOuIH0wgBRgRIXvFPBtA5hiOOmKqsWPLDExRUNJ8/+zi9ceuhEdZ2aHEiSmB+0Si2IS3g3yt69LSg70j6E4z1MGDA99x4HzVT/wsRAEVoHiO4IA3fGmQeH1IV6bY+033zpKEI9murL3O54AdPiLVNfm42R0CtjHeUwo6mM76plYrCQpnhcIYLsm1aYsmFLwU6E7MzcRUHMaapX0axNwz5LwMWP1GgKdR4blldByjhr46IC+YQpO6d7sQMMKVeHYsQX6IbtnkNw4jjOE/FJaMMn1Y+1cW2NHCj52ajF0ucAmXjJUdmgy5gTo+TUWiuJZdVfEGW7uPnFrlG5EBrKIYpRD5r0p7EAtJgI/OBgXKWrYbGO0EmYL7rwH6ry1W0P+/8/UKCBAAMCDIMAZPYChIgx5IgBgkOgICsvBjeRopDovDQRFoOEYPSC33w0Gn1Kr1is1qt9xuQNANi8WisZk7YJwPgXNVABvI5/S6Xc4g6Pd6hAIcNWUy8FCgg2CoAiCyY/hkCPBUlgNhU5CwACawoAPhIGCAkAI4AlkAcehoEDoK5aAwImLQBsCy+PcgCmDJxCkH1Ri5Smsb8JWQBnCqc0A4ABnoJj1NXf1Vjc01mT0tAB3mnY18R16ex6cHUZSQ8zslMNBTIED7y0gMNmAMAbZNDzXpXrRrOQowMCawFjwcBFstuhGoTIEGCwawM7CARht3I/4pdPeLoLtJAtj/TeHIDYCRlCynNWzZchvMmTSxCeATwIENKigFCfCoYEnCLw44KXyYYwcUCJBQeXT3csGShx6/QCV19OGrH0KBKWgAoJKOjVLGjtpKYolIHDJ5luXWs6ZcKi/nUmtrN69eKjsUPMiCEh47OPMQJWjAbqiAojoa9JvS4C8oBiiSeTTQ4JJjKFJVKsasGSvjmwAOJzCN1MCBXagqFUACMSk+06jXxgL8NlvcvTXr8h6D97fw4SfLFnBgjMFgiplS7IIFQIENJAOk15qS4KCCAgX0PXueY0X1naUyrgAf3YZ461D0ndexoPl1ZUgW2JhVBNbKHC2E2NgkH3v70XLFbtUY/0gcNwGgw2CDDj4IYYQRJkhhhQh2RGCFGtp1YQEPfDXGTxuOqMWFJJ6IYnFZ9Jdii9jsBs+Ce7hI4xgm1ojjcDfmyGMYHBlQFAQNcjQOkXT0SOKOSC45k5JMPtmeFAcw0ICDRs6RQ5G5Qcmbk1x+6YaXW4iYkm+xTWEAJAeYtAabWySw2mnTxAXkAkLOCGaOYubJ5xZ7ZkGmgli1syVBa0pzaBdwnnnGhfAgEFyfI/4paaUqhqGAAgs0YIMMNHS6WqZJDCqqYz0YBQQODszAz3wr/eKCMQUY4EQb1gWARGaHGLMaFDL4cOsKq8yAQALW9ddfAw2w8GuGfm5JxTeWJv8J7bR90jMAeVaIGcBqSkHygC8odAtAuFOQm4sqs6QwbCtl/PILJEFldQ0B7MzLFKOg7XIUAX+cYkkC1/zzz0iGaPustVBSqjCON6UjlZuEikGQLBnNANHAzmo8CkhY9hvILyskMS4g9UbxVFkonWxWDhwXjEMPAwxaYrUNu8jwzTAl8MlPPv8MdNA+O9BgAwwcAA23YCwjFsxHeeSyJvigNYADVyEFb7a6hmTyYzek3B507nakSysEk8WfAxBIjJvOSObsdkoCQGBM3XbfjbfdkBbNwF/ReLFaMq7BxnXLUbd8DGKmgXYYGJwKXJnWlwSAQhGJeP2LaxVBkcDaAKj/5TUAkelgAAMOvNbGPw6o0R13nPpoc9zU3mxASW/MPMKiNUHtxsMQO8A2txl9h98RKoV6n9j+oWcdgICs918Apq+2EhvT7xJfeq6uhhEDlL2T0RK3ZqndJfEZ359BAfBsjN9dwC17XvC3GApl0r+DACgJ0cT7GTdRjrBLeYFmTPJGAcxkodjFT0PzS1H++DMF73lDavDYyXEsoow0EbAL/TMDdxKGqQAyCTmKSFEDF0iTE5IIM1gwhkUYAYEDPAAxB5RhseCAsd45K4UKROGGVOhDlgBxQ/0bR+DY0rKgEOEnlAmGNDrYpB4GkUJDnOKLpLgkFkJhHqCITULmQDk5//xkhyEiI0yqaEW4YDGN8lsjkjYzAoSNpGULeAAbCgJFMeSxJWkQmh//CMhACnKQhCykIQ+JSJ99j42TcmOPMGM/NUTpNnNTwEFGcJB4fMKM4OAkS9iQt1CKcpSkLKUpT4nKVKpylXbrFSMZ6EjiHGGDVqidtEpjkqWtQlsJsN2sqLHHVwpzmG3s0QD2kBMRuiiYxGymM1PSx0RKc5qKZBAEjsY2uXDRkMh5pje/+UlWinOcd6uSgxA4k1msUnngpIIr2wnPPB2TD36g5Qh04s5sVqF18aQJWPoJ0IURwGiF2MKUqoBOd0oyoNy4iTIZClEUySkMiOhI1S6nDAecDv+XymDHL2uhz4jaiACxFKlJUyQA6ORiMaCbiBEyY65VfU6lJT2pywjgSZvqlEaEuOcC2PQF40UHaagIwE/7Voqc7tQKBcDTUp+KI9wpowQQ+ItVcPCL/B1NBtBQKlSh8IA9uO+rZCWRA/wGrjZ8wVwAQKqmCtGDghilrFlQwB7YSde8Dqd096QcAlZzDeldshMjWIDYDjAVvVphbwQom2Ify5v15c52u4DEKqCwk4lG4paQTQA6QgrZ0LbEiW5YpGhzcAB0vPO0rG2JAUCrhXm0Nks/IcBPYDvb3Oo2QZHarW9/+5veAne4xJ2JcIuL3OTOSbnMba5znwvd6Ep3utT/ra51K+TV62pXt8fdrndb293vihey4R2veela0/Oqd73sba979ToHmgVKHLi1AgJ/JaKEvne/crHtDlY73yueAYH5yq89rZtd/takDP8YQhFWUqpN+CASNICOCnICHb7mQFksUKctjgWdX3FCeqPyFU6HANj4vO6An1LJ6qQzA8Q0t7wKNu4P1GCMkoRkNekShjJGIIl/ec50kwRAczbxtDbsywbomuttMiYZUTTnMCSIzCz+cokZ15i3NFgARjMmtVboIwCtmoQcJvKNOd6GYysLM0ACUbFF1E0E7nBAA4awz5/h0Wd7DtQ2SfHnPgNaz6UgtDIMHehC81nRfka08qMXfWhIJzrSja7tlokjE9twTCGMAVnuYrjQaOQrLEkmgfI2nYN3lUwZqCBAmqUAp79SwcMEojV/7HbruuXaGLuuNa7j+OtdBNvWwNZ1sXl9bF8bW9jLJjazkf1sZd/v0sLJNCAKV5XFcAIOoWurvaawOmV8LxmmQ11pPAc6wz15xyRQgyW5s4Q6s6Mz1K63FpwlIOQxbzqUGx9qnVyKgySgO5QzBCby05HwaY9FLhsBhDMJCRIuYT/hopy9Ly4c/WJ840HMDsc/DvKQi3zkJC+5yU+O8pSrfOUsb7nLXw7zmMt85jSvuc1vjvOc63znNQoBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transmission of incoming nociceptive impulses is modulated by dorsal horn circuitry that receives input from peripheral touch receptors and from descending pathways that involve the limbic cortical systems (orbital frontal cortex, amygdala, and hypothalamus), periaqueductal endogenous analgesic center in the midbrain, pontine noradrenergic neurons, and the nucleus raphe magnus (NRM) in the medulla. Dashed lines indicate inhibition or modulation.",
"    <div class=\"footnotes\">",
"     * Location of opioid receptors.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_29_21983=[""].join("\n");
var outline_f21_29_21983=null;
